Digestive system carcinoma
MONDO:0006181A malignant neoplasm that arises from the epithelium of any part of the digestive system. Representative examples include colorectal carcinoma, esophageal carcinoma, and pancreatic carcinoma.
Also known as: carcinoma of digestive system, carcinoma of the gastrointestinal system, digestive system carcinoma, gastrointestinal carcinoma, gastrointestinal carcinoma (disease), gastrointestinal system carcinoma
7112 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 3120 trials in this tab.
-
Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether giving a combination of two immunotherapies (ipilimumab and sintilimab) along with chemotherapy and radiation before surgery can completely eliminate cancer cells in people with locally advanced esophageal cancer. About 44 adults with resectable esop…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: ⭐️ CURE ⭐️
Last updated Aug 09, 2026 00:00 UTC
-
Aiming to spare the anus: a new strategy for early rectal cancer
⭐️ CURE ⭐️ Recruiting nowThis trial is testing a combination of local tumor removal and chemoradiotherapy (radiation plus capecitabine chemotherapy) in people with early-stage rectal cancer located low in the rectum. The goal is to see if this approach can effectively treat the cancer while avoiding the …
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: ⭐️ CURE ⭐️
Last updated Aug 05, 2026 00:00 UTC
-
Can a triple-drug cocktail after short radiation eliminate rectal cancer without surgery?
⭐️ CURE ⭐️ Recruiting nowThis trial is testing whether adding two immunotherapy drugs—zimberelimab and etrumadenant—to standard chemotherapy and a short course of radiation can completely eliminate rectal cancer. Adults with locally advanced rectal cancer that has not spread will receive the treatment, a…
Phase: PHASE2 • Sponsor: Weill Medical College of Cornell University • Aim: ⭐️ CURE ⭐️
Last updated Jul 31, 2026 00:00 UTC
-
Robotic surgery may spare throat cancer patients from chemo and radiation
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial is testing whether robotic surgery alone can control HPV-related throat cancer, potentially sparing patients the long-term side effects of chemotherapy and radiation. The study enrolls people with HPV-positive oropharyngeal cancer whose tumors are removable and…
Phase: PHASE2 • Sponsor: Icahn School of Medicine at Mount Sinai • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Triple attack on bile duct cancer: chemo, targeted drug, and immunotherapy aim to make the inoperable operable
⭐️ CURE ⭐️ Recruiting nowThis phase 2 trial tests whether a combination of three treatments can shrink inoperable intrahepatic cholangiocarcinoma (a type of bile duct cancer) enough to allow surgical removal. The approach delivers chemotherapy directly into the liver's blood supply (HAIC) along with the …
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: ⭐️ CURE ⭐️
Last updated Jul 24, 2026 00:00 UTC
-
Smart drugs take on rare salivary gland cancer in new trial
Disease control Recruiting nowThis phase II trial is testing whether newer targeted drugs (trastuzumab emtansine and trastuzumab deruxtecan) work better than standard chemotherapy plus trastuzumab for people with HER2-positive or HER2-low salivary gland cancer that has come back, spread, or cannot be removed.…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for colorectal cancer: experimental drug faces off against avastin
Disease control Recruiting nowThis Phase 3 trial is testing whether a new medicine called PF-08634404, combined with standard chemotherapy, works better than the current treatment Avastin plus chemo for people whose colorectal cancer has spread. About 800 participants who have not had prior treatment for meta…
Phase: PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo aims to shrink tumors and cut radiation for young cancer patients
Disease control Recruiting nowThis study tests whether adding the immunotherapy drug nivolumab to standard chemotherapy (gemcitabine and cisplatin) before radiation therapy is safe and effective for children and young adults (up to age 21) with newly diagnosed nasopharyngeal carcinoma. The goal is to see if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Last-Resort drug access opens for advanced pancreatic cancer patients
Disease control AVAILABLEThis program offers daraxonrasib to adults with metastatic pancreatic cancer that has worsened after prior treatment and who have no other good options. It is for patients who cannot join ongoing clinical trials. The goal is to provide access to this experimental drug when no sta…
Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New Dual-Action antibody takes on advanced cancers
Disease control Recruiting nowThis study tests a new drug called AI-081 in people with advanced solid tumors that have spread or cannot be removed by surgery. The drug is a bispecific antibody that targets two proteins (PD-1 and VEGF) involved in cancer growth and immune evasion. The trial has two phases: fir…
Phase: PHASE1, PHASE2 • Sponsor: OncoC4, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Less neck surgery may spare shoulder function in oral cancer patients
Disease control Recruiting nowThis study tests whether a less invasive surgery called sentinel lymph node biopsy can replace standard neck dissection for early-stage oral cavity cancer. About 686 patients will be randomly assigned to one of the two procedures. The goal is to see if the gentler approach mainta…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study tests a new oral drug, VS-7375, alone or with another drug (cetuximab), in 180 people with metastatic pancreatic cancer that has a specific genetic change called KRAS G12D. The goal is to see if the drug shrinks tumors and is safe. Participants must have this mutation …
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for advanced cancers? pfizer launches early trial of PF-08046033
Disease control Recruiting nowThis early-stage study tests a new medicine called PF-08046033 in adults with advanced lung, esophageal, or skin cancers that have spread or can't be removed. The main goal is to check safety and find the right dose. Researchers will also look for early signs that the drug may he…
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a stronger radiation blast tame pancreatic cancer?
Disease control Recruiting nowThis phase III trial tests whether giving a higher dose of radiation can help people with locally advanced pancreatic cancer live longer. Participants must have already had 4-6 months of chemotherapy. The study compares higher-dose radiation to standard care (more chemo, observat…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug combo trial aims to fight advanced cancers
Disease control Recruiting nowThis study tests a new drug called BMS-986340, alone or with other cancer treatments, in people with advanced solid tumors like lung, colon, or breast cancer. The goal is to find safe doses and check for side effects. About 1,100 adults with tumors that have worsened after standa…
Phase: PHASE1, PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for advanced cancer: APR-1051 enters first human trial
Disease control Recruiting nowThis early-stage study tests a new oral drug, APR-1051, in about 90 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Researchers will also look for early signs that the drug might…
Phase: PHASE1 • Sponsor: Aprea Therapeutics • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Immune cell boost plus targeted procedure shows promise for inoperable liver tumors
Disease control Recruiting nowThis Phase 2 trial tests whether adding a special immune cell infusion (GKL-006) to a standard procedure that blocks blood flow to tumors (TACE) can shrink liver cancers that cannot be removed by surgery. About 48 adults with unresectable hepatocellular carcinoma will receive the…
Phase: PHASE2 • Sponsor: Beijing Gene Key Life Technology Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can a Dual-Action antibody outsmart resistant tumors?
Disease control Recruiting nowThis early-stage trial is testing an investigational drug called GIM-122 in adults with advanced solid tumors that have not responded to standard treatments, including PD-1/PD-L1 inhibitors. GIM-122 is a special antibody designed to fight cancer in two ways. The study aims to fin…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Can spreading out radiation beat a single dose for brain tumors?
Disease control Recruiting nowThis Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New smart drug targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called M7437 in people with advanced solid tumors that have not responded to standard treatments. M7437 is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells that have a specific marker (Ly6E). The study ai…
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
How far should surgeons go? a trial tests deeper lymph node removal for colon cancer
Disease control Recruiting nowThis trial asks whether removing a wider set of lymph nodes (D3) during left colon cancer surgery improves 5-year survival compared to the standard removal (D2). It enrolls about 1,381 people with adenocarcinoma located between the splenic flexure and rectosigmoid junction. Resea…
Phase: NA • Sponsor: Russian Society of Colorectal Surgeons • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for head and neck cancer: which drug works best with radiation?
Disease control Recruiting nowThis study compares two treatments for people with advanced head and neck cancer who cannot use the standard drug cisplatin. About 454 participants will receive either cetuximab (a targeted antibody) or a chemotherapy combo (carboplatin + paclitaxel) alongside precise radiation t…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
Could an immunotherapy boost help fight stomach cancer?
Disease control Recruiting nowThis clinical trial is testing whether adding the immunotherapy drug nivolumab to standard chemotherapy (paclitaxel and ramucirumab) can help people with advanced stomach or esophageal cancer live longer. The study includes 224 adults whose cancer has a specific marker (PD-L1 CPS…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug FOG-001 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug, FOG-001, in about 595 people with advanced or metastatic solid tumors, including colorectal, prostate, and liver cancers. The drug is given alone or with other cancer treatments to see if it is safe and shrinks tumors. The study is cu…
Phase: PHASE1, PHASE2 • Sponsor: Parabilis Medicines, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New pill targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis early-stage study is testing an experimental oral drug, VVD-133214, in people with advanced solid tumors that have specific genetic features (MSI or dMMR). The drug works by blocking a protein that helps these cancers grow. The study will check safety and how well the drug w…
Phase: PHASE1 • Sponsor: Vividion Therapeutics, Inc. • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy aims to buy more time for bile duct cancer patients
Disease control Recruiting nowThis study compares standard chemotherapy (gemcitabine and oxaliplatin) alone versus the same drugs plus a liver-directed chemotherapy (HAI FUDR/dexamethasone) in people with bile duct cancer that has spread within the liver but cannot be removed surgically. About 164 adults with…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New combo therapy aims to boost radiation for tough pancreatic tumors
Disease control Recruiting nowThis early-phase trial tests a drug called XER-001 (a form of amifostine given through a tube into the small intestine) combined with precise radiation therapy for people with locally advanced pancreatic cancer that cannot be removed by surgery. The study will enroll 36 participa…
Phase: PHASE1, PHASE2 • Sponsor: Xerient Pharma • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for advanced liver cancer: radiation boosts immunotherapy in major trial
Disease control Recruiting nowThis phase 3 trial is for people with advanced liver cancer that has spread to nearby blood vessels. It compares standard immunotherapy drugs (atezolizumab and bevacizumab) alone versus the same drugs plus targeted radiation (SBRT). The goal is to see if adding radiation helps pa…
Phase: PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for advanced bowel cancer: experimental drug combo enters major trial
Disease control Recruiting nowThis study tests whether a new drug called pumitamig, combined with chemotherapy, works better than the current standard treatment (bevacizumab plus chemo) for people with advanced colorectal cancer that cannot be removed by surgery. About 990 adults who have not yet been treated…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New cocktail of drugs could shrink stomach tumors before surgery
Disease control Recruiting nowThis study tests several new drug combinations given before and after surgery for stomach or esophageal cancer. About 100 people with resectable tumors will receive these treatments to see if they are safe and can shrink or eliminate the cancer. The goal is to improve outcomes by…
Phase: PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New hope for liver cancer: pfizer tests experimental drug
Disease control Recruiting nowThis study tests a new drug called PF-08634404, given alone or with another drug (ipilimumab), in adults with advanced liver cancer that cannot be surgically removed. The goal is to check safety, side effects, and whether the drug shrinks tumors. About 138 participants will recei…
Phase: PHASE1, PHASE2 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New pill combo aims to fight stomach cancer when first treatment fails
Disease control Recruiting nowThis study tests whether taking oral paclitaxel plus fruquintinib can help people with advanced stomach or gastroesophageal junction cancer after their first treatment stops working. About 150 adults will receive either the new drug combo or standard chemotherapy chosen by their …
Phase: NA • Sponsor: Harbin Medical University • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New targeted combo aims to outsmart Hard-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding the targeted drugs calderasib and cetuximab to standard chemotherapy can help people with a specific gene mutation (KRAS G12C) in advanced colorectal cancer live longer without their cancer growing. About 477 participants will receive …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New pfizer combo aims to outperform current therapy for stomach cancer
Disease control Recruiting nowThis study tests a new experimental drug, PF-08634404, combined with chemotherapy in people with advanced stomach, gastroesophageal junction, or esophageal cancer that has not been treated before. The trial has two parts: first checking safety and response, then comparing the new…
Phase: PHASE2, PHASE3 • Sponsor: Pfizer • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug targets tough cancers in early trial
Disease control Recruiting nowThis study tests a new drug called YH42946 in people with advanced solid tumors that have certain gene changes (HER2 or EGFR). The main goals are to check safety and see if the drug shrinks tumors. About 161 adults who have run out of standard options will take part.
Phase: PHASE1, PHASE2 • Sponsor: Yuhan Corporation • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug cocktail targets rare bile duct cancer
Disease control Recruiting nowThis study tests whether combining three drugs—pemigatinib, atezolizumab, and bevacizumab—can help control advanced bile duct cancer that has a specific genetic change (FGFR2 fusion). About 25 adults whose cancer has not responded to other treatments will take part. The main goal…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug SHR-4610 tested in patients with Hard-to-Treat cancers
Disease control Recruiting nowThis study tests an experimental drug called SHR-4610 in 258 adults with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The trial has two phases: first, finding the safest dose, and second, checking how well the drug shrinks…
Phase: PHASE1, PHASE2 • Sponsor: Shanghai Shengdi Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 18, 2026 04:00 UTC
-
New drug TUB-030 targets Hard-to-Treat cancers in early trial
Disease control Recruiting nowThis trial tests a new drug called TUB-030 in adults with advanced solid tumors, including head and neck, lung, and breast cancers. The goal is to find the safest and most effective dose. Participants receive the drug every three weeks and are monitored for side effects and tumor…
Phase: PHASE1, PHASE2 • Sponsor: Tubulis GmbH • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New chemo delivery method aims to shrink untreatable colon tumors
Disease control Recruiting nowThis study tests a procedure called transarterial infusion chemotherapy (TAIC) for people with colorectal cancer that cannot be removed by surgery. Instead of giving chemo through a vein, TAIC delivers it directly to the tumor's blood supply, which may boost effectiveness and red…
Phase: NA • Sponsor: Quanda Liu • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers with MET gene change
Disease control Recruiting nowThis phase 2 study tests an investigational drug called telisotuzumab adizutecan in about 100 people aged 12 and older with advanced solid tumors that have a specific genetic change (MET amplification). The drug is given through an IV and aims to shrink tumors or stop them from g…
Phase: PHASE2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Could simple Over-the-Counter drugs supercharge cancer immunotherapy?
Disease control Recruiting nowThis study tests whether adjusting common over-the-counter medications can make immune checkpoint inhibitors work better for people with solid tumors. Participants are asked to avoid acetaminophen and cannabis/THC/CBD, while taking aspirin and loratadine (or similar antihistamine…
Phase: PHASE2 • Sponsor: Val Adams • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to boost immune attack on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental oral drug called GIM-531, alone or with an immunotherapy (anti-PD-1), in 117 adults with advanced solid tumors that have stopped responding to standard treatments. The goal is to see if the drug is safe, tolerable, and can help th…
Phase: PHASE1, PHASE2 • Sponsor: Georgiamune Inc • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced liver cancer: immunotherapy cocktails under study
Disease control Recruiting nowThis clinical trial is testing several combinations of immunotherapy drugs to see if they can shrink or control advanced liver cancer. The study is for people with a type of liver cancer called hepatocellular carcinoma (HCC) that has spread or cannot be removed by surgery. Partic…
Phase: PHASE1, PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for advanced cancer: experimental drug CR-001 enters human trials
Disease control Recruiting nowThis study tests a new drug called CR-001 in adults with advanced solid tumors that have spread. The goal is to find the safest dose and see if it can shrink tumors. About 290 people will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: Crescent Biopharma, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill shows promise in early cancer trial
Disease control Recruiting nowThis early-phase study is testing a new oral drug called BG-75202, alone or with other medications, in people with advanced breast cancer or other solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and …
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New antibody combo aims to outperform standard therapy in Tough-to-Treat colorectal cancer
Disease control Recruiting nowThis phase 3 trial tests whether a new drug called petosemtamab, combined with chemotherapy, works better than the current standard treatment (cetuximab plus chemotherapy) for people with left-sided colorectal cancer that cannot be surgically removed or has spread. The study incl…
Phase: PHASE3 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill plus chemo aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis Phase 3 trial tests whether adding an experimental oral drug called atebimetinib to a modified chemotherapy regimen helps people with metastatic pancreatic cancer live longer. About 510 adults who have not had prior treatment will receive either the new combination or standa…
Phase: PHASE3 • Sponsor: Immuneering Corporation • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug CS5007 targets tough cancers in first human trial
Disease control Recruiting nowThis early-stage trial tests a new drug called CS5007 in people with advanced solid tumors that cannot be removed by surgery. The drug is designed to seek out and attack cancer cells while sparing healthy ones. The study will first find the safest dose and then check if the drug …
Phase: PHASE1 • Sponsor: CStone Pharmaceuticals • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can radiation kickstart the immune system against stubborn GI cancers?
Disease control Recruiting nowThis study is for people with advanced gastrointestinal cancers that are growing despite immunotherapy. Researchers want to see if adding targeted radiation to one tumor can help the immune system attack other tumors throughout the body. About 28 participants will receive radiati…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on advanced cancers in first human test
Disease control Recruiting nowThis early-stage study tests a new tablet called GW01-200 in 100 people with advanced solid tumors or blood cancers that have stopped responding to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participan…
Phase: PHASE1 • Sponsor: Groovy Medicine (Hangzhou) Ltd. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Can targeted liver chemo turn inoperable tumors into operable ones?
Disease control Recruiting nowThis trial tests whether delivering chemotherapy directly to the liver through a pump, combined with standard systemic chemotherapy, can shrink liver tumors from colorectal cancer enough to allow surgery. The study enrolls people whose liver metastases are initially inoperable bu…
Phase: PHASE2 • Sponsor: Sunnybrook Health Sciences Centre • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Blood test could guide anal cancer treatment, reducing side effects
Disease control Recruiting nowThis study tests whether a blood test (ctDNA) can help doctors customize the dose of chemoradiation for people with anal cancer. Depending on how the tumor responds, some patients may get a lower radiation dose to reduce side effects, while others may get a higher dose or an adde…
Phase: PHASE2 • Sponsor: Jennifer Dorth • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill takes on tough pancreatic cancer in major trial
Disease control Recruiting nowThis study tests a new daily pill, GFH375, against standard chemotherapy in 320 people with advanced pancreatic cancer that has a specific KRAS G12D gene mutation. Participants must have already tried at least one standard treatment. The goal is to see if the new drug helps peopl…
Phase: PHASE3 • Sponsor: Genfleet Therapeutics (Shanghai) Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for pancreatic cancer: experimental drug combo enters large trial
Disease control Recruiting nowThis large Phase 2/3 trial is testing whether adding an investigational drug called telisotuzumab adizutecan to standard chemotherapy (FOLFOX) can help people with metastatic pancreatic cancer live longer or shrink their tumors. About 900 participants will be randomly assigned to…
Phase: PHASE2, PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Triple-Drug attack on stomach cancer shows promise in major trial
Disease control Recruiting nowThis study tests whether adding a second immunotherapy drug (ipilimumab) to the standard combination of sintilimab and chemotherapy helps shrink stomach tumors before surgery and keeps cancer from coming back afterward. About 720 adults with resectable stomach or gastroesophageal…
Phase: PHASE2, PHASE3 • Sponsor: Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug combo shows promise in shrinking liver tumors before surgery
Disease control Recruiting nowThis trial tests whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery can shrink high-risk liver cancer (cholangiocarcinoma) and reduce the amount of tissue that needs to be removed. About 27 patients with resectable tumors will receive…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New drug MRG007 enters early human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial tests a new drug called MRG007 (ARR-217) in people with advanced solid tumors that have not responded to standard treatments. The study aims to find a safe dose and check if the drug can shrink tumors. About 405 participants with colorectal, gastric, or pan…
Phase: PHASE1 • Sponsor: ArriVent BioPharma, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug YL211 enters first human tests
Disease control Recruiting nowThis early-stage trial tests a new drug called YL211 in 155 people with advanced solid tumors who have no standard treatment options left. The study has three parts: first, finding a safe dose; then, confirming that dose; and finally, testing how well it works. The main goals are…
Phase: PHASE1 • Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Engineered immune cells take aim at stubborn cancers
Disease control Recruiting nowThis study tests a new therapy where a person's own white blood cells are collected, genetically modified in a lab to recognize and attack cancer cells with a specific mutation (KRAS G12V), and then infused back. Participants also receive chemotherapy and a drug to boost cell act…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could your own tumor cells fight cancer? new trial tests immune cell therapy
Disease control Recruiting nowThis phase 2 trial tests whether specially selected immune cells taken from a patient's own tumor, grown in large numbers in the lab, and given back along with the drug pembrolizumab (Keytruda) can shrink tumors in people with metastatic colorectal, pancreatic, ovarian, breast, o…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets cancer DNA in advanced tumors
Disease control Recruiting nowThis early-phase study tests CBX-12 in about 35 adults with advanced solid tumors that have spread and stopped responding to prior treatments. CBX-12 works by entering cancer cells and damaging their DNA, which can kill the cells. Researchers will measure how well the drug trigge…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a vaccine help fight Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental vaccine called YMN-136 in people with advanced liver, pancreatic, or biliary tract cancer that has progressed after standard treatment. The main goal is to check the vaccine's safety and find the best dose, while also seeing if it…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New Dual-Antibody drug takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis study tests OTP-01, a new drug that targets two cancer pathways (PD-1 and VEGFR2) at once, in 170 adults with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find the best dose, check safety, and see if the drug can shrink tum…
Phase: PHASE1, PHASE2 • Sponsor: Ottimo Pharma Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Experimental combo aims to tackle stubborn colorectal cancer
Disease control Recruiting nowThis trial is testing whether combining pidnarulex (a drug that blocks cancer cell growth) with cemiplimab (an immunotherapy that helps the immune system attack cancer) is safe and effective for people with advanced colorectal cancer that no longer responds to standard treatments…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Smart patch lets gut surgery patients go home days earlier
Disease control Recruiting nowThis study tests a wearable patch called MultiSense that tracks heart rate and other vital signs for five days after a patient leaves the hospital following major digestive surgery. The goal is to see if the patch allows high-risk patients to be discharged earlier while still cat…
Phase: NA • Sponsor: Rhythm Diagnostic Systems • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Biomarker-Guided combo aims to outsmart tough cancers
Disease control Recruiting nowThis phase II trial is testing whether the combination of cabozantinib (a targeted therapy) and nivolumab (an immunotherapy) can shrink or stabilize advanced melanoma and head and neck cancers that have stopped responding to prior immunotherapy. Researchers are also checking if t…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: GTAEXS617 enters human trials
Disease control Recruiting nowThis study tests a new drug called GTAEXS617 in people with advanced solid tumors (like lung, pancreatic, or ovarian cancer) that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 230 p…
Phase: PHASE1, PHASE2 • Sponsor: Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New drug targets tough pancreatic cancer in early trial
Disease control Recruiting nowThis phase 2 study tests an experimental drug called BT5528 in adults with metastatic pancreatic cancer that has spread and worsened after one prior treatment. The drug targets a specific protein on cancer cells. Researchers will measure how well it shrinks tumors and track side …
Phase: PHASE2 • Sponsor: BicycleTx Limited • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a pill turn on genes that stop cancer? new trial begins
Disease control Recruiting nowThis early-phase trial tests a new drug called Aza-TdC in adults with advanced solid tumors that have worsened after standard treatment or have no effective therapy. The drug is taken by mouth in 21-day cycles and aims to reactivate genes that may slow tumor growth. The main goal…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
Disease control Recruiting nowThis early-phase trial is testing whether combining two experimental drugs, JAB-21822 and JAB-3312, can safely shrink or control advanced solid tumors that carry a specific KRAS G12C mutation. The study includes people with cancers like non-small cell lung, colorectal, or pancrea…
Phase: PHASE1, PHASE2 • Sponsor: Allist Pharmaceuticals, Inc. • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a blood test and MRI tailor cancer therapy to each patient?
Disease control Recruiting nowThis trial tests whether giving extra chemotherapy or a combination of chemotherapy and immunotherapy after standard treatment can improve outcomes for people with nasopharyngeal carcinoma. The choice of treatment is based on each patient's risk level, determined by changes in a …
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
MRNA vaccine takes on liver cancer in tiny early trial
Disease control Recruiting nowThis early study tests a PD-1 mRNA vaccine in 9 adults with advanced liver cancer that has not responded to standard treatments. The vaccine is given as weekly shots for four weeks, then a fifth shot a month later. The main goal is to check safety, but researchers will also see i…
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New antibody takes aim at Hard-to-Treat liver cancer
Disease control Recruiting nowThis study tests a new drug called AZD9793 in people with advanced liver cancer that has spread. The drug is an antibody designed to help the body's immune cells find and attack cancer cells. The main goals are to check if the drug is safe and if it can shrink tumors. About 304 a…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Could a cancer drug slow bile duct tumors?
Disease control Recruiting nowThis study tests a drug called tivozanib in people with bile duct cancer that cannot be removed by surgery and has already been treated with chemotherapy. The goal is to find the safest dose and see if the drug can shrink tumors or slow the cancer. Participants take tivozanib by …
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New cancer drug BNT3214 enters human trials for advanced tumors
Disease control Recruiting nowThis study is the first time the drug BNT3214 is being tested in people. It aims to find a safe and effective dose for adults with advanced solid tumors. The trial has three parts: first, finding the best dose; then, testing it in different cancer types. About 533 participants wi…
Phase: PHASE1, PHASE2 • Sponsor: BioNTech SE • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New liposomal drug takes on advanced cancers
Disease control Recruiting nowThis study tests an experimental drug called SMP-3124LP, which is a liposomal (fat-encapsulated) version of a cancer-fighting compound. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial has two parts: first, finding the safest d…
Phase: PHASE1, PHASE2 • Sponsor: Sumitomo Pharma America, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Pancreas cancer surgery showdown: total removal may boost survival
Disease control Recruiting nowThis study looks at whether removing the entire pancreas is better than removing just part of it for people with certain cancers in the head of the pancreas who are at high risk of complications. The main goal is to see if total removal helps patients live longer without hurting …
Phase: NA • Sponsor: Insel Gruppe AG, University Hospital Bern • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Spirulina's secret protein may shield the liver during surgery
Disease control Recruiting nowThis trial tests whether phycocyanin, a natural protein from spirulina, can reduce liver injury and support recovery in adults having part of their liver removed due to intrahepatic cholangiocarcinoma. About 30 participants will take either phycocyanin or a placebo daily for thre…
Phase: NA • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Can a pill outsmart Tumors' defenses?
Disease control Recruiting nowThis trial tests an experimental oral drug called TT-702 in people with advanced solid tumors. The drug works by blocking a protein that tumors use to hide from the immune system. The study aims to find the safest dose of TT-702 when given alone and in combination with an immunot…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-phase study tests a combination of two drugs (BMS-986504 and olaparib) in adults with advanced solid tumors that have lost a gene called MTAP. The main goal is to find safe doses and understand side effects. About 36 people will take part, and the study is currently re…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New pill aims to speed liver healing after cancer surgery
Disease control Recruiting nowThis study tests an experimental drug called HRX215 in people who had part of their liver removed because colon cancer spread there. The drug is meant to help the liver grow back and work better after surgery. About 80 adults will take either HRX215 or a placebo for 28 days, and …
Phase: PHASE1, PHASE2 • Sponsor: HepaRegeniX GmbH • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced cancer: first human trial of FP008 begins
Disease control Recruiting nowThis early-stage study tests a new drug called FP008 in 108 adults with advanced solid tumors that have not responded to other treatments. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug works in the body and whether…
Phase: PHASE1 • Sponsor: Zhuhai Fapon Biopharma Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for bile duct cancer: drug may delay return after surgery and chemo
Disease control Recruiting nowThis study tests a drug called ivosidenib in people with a specific type of bile duct cancer (IDH1-mutated) that has been surgically removed. After standard chemotherapy, participants take ivosidenib daily to see if it helps keep the cancer from returning. The trial involves 40 a…
Phase: PHASE2 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Could a tailored diet before surgery boost liver cancer recovery?
Disease control Recruiting nowThis trial tests whether a personalized nutrition plan, combined with exercise and psychological support before surgery, can improve outcomes for people with primary liver cancer. Participants are randomly assigned to receive either standard dietary advice or an enhanced program …
Phase: NA • Sponsor: Second Affiliated Hospital, Zhejiang University, School of Medicine • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer drug SHR-4298 enters early human testing
Disease control Recruiting nowThis study is testing an experimental drug called SHR-4298 in 200 people with advanced solid tumors that cannot be removed by surgery or cured by standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors or slow cancer…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New virus therapy takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase study tests a new treatment called MQ710, a modified virus injected directly into tumors, alone or with the immunotherapy drug pembrolizumab. It is for people with advanced solid tumors (like skin cancer or head and neck cancer) that have not responded to standar…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug COM503 enters first human trial for advanced cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called COM503, alone or with another drug zimberelimab, in 200 people with advanced solid tumors that have not responded to standard treatments. The main goal is to check safety and find the right dose. It is a first-in-human study, so effe…
Phase: PHASE1 • Sponsor: Compugen Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug pumitamig takes on nivolumab in stomach cancer showdown
Disease control Recruiting nowThis study compares two drug combinations for people with advanced stomach, gastroesophageal junction, or esophageal cancer that hasn't been treated yet. One group gets pumitamig plus chemotherapy, the other gets nivolumab plus chemotherapy. The goal is to see which combo works b…
Phase: PHASE2, PHASE3 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New immune drug PHST001 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing a new drug called PHST001, which helps the immune system attack cancer cells by blocking a protein called CD24. The study will first test PHST001 alone, then in combination with standard chemotherapy, in adults with advanced solid tumors (includi…
Phase: PHASE1 • Sponsor: Pheast Therapeutics • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: drug combo aims to make tumors removable
Disease control Recruiting nowThis study tests a new drug (HRS-4642) combined with standard chemotherapy (nab-paclitaxel and gemcitabine) in 30 people with locally advanced pancreatic cancer that has a specific gene change (KRAS G12D). The goal is to shrink tumors enough to allow surgery. Participants will ha…
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New antibody drug combo targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug called AZD8205, alone or with another drug (rilvegostomig), in people with advanced solid tumors like breast, ovarian, and lung cancers. The trial has two phases: first to find the safest dose, then to see if it shrinks tumors. About 460 adults whose c…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New drug cocktail targets Hard-to-Treat tumors
Disease control Recruiting nowThis study tests an experimental drug called AZD9574, taken alone or with other anti-cancer medicines, in about 695 people whose advanced solid tumors have grown despite prior treatment. The main goals are to check the drug's safety and find the right dose. Researchers will also …
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New biologic drug GEN1106 enters first human tests for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new biologic drug, GEN1106, in about 103 people with advanced solid tumors, including bladder cancer. The study has three parts: first, finding a safe dose; then refining it; finally, checking how well the drug shrinks tumors. All participants …
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for advanced tumors? first human trial of DS-3939a begins
Disease control Recruiting nowThis early-phase study tests a new drug called DS-3939a in about 540 people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safety and see if the drug shrinks tumors. Participants must have measurable disease and good organ function.
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New combo therapy aims to stop head and neck cancer from returning
Disease control Recruiting nowThis phase II trial is testing whether adding chemotherapy or chemo-immunotherapy before standard salvage surgery can improve outcomes for patients with PD-L1 positive head and neck cancer that has come back. About 180 participants will receive either carboplatin and paclitaxel, …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody M0324 enters first human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study is testing a new drug called M0324, a bispecific antibody designed to target cancer cells. The trial will look at M0324 alone, with the immunotherapy pembrolizumab, and with chemotherapy in about 77 people with advanced solid tumors that have not responded …
Phase: PHASE1 • Sponsor: EMD Serono Research & Development Institute, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a bile acid blocker prevent esophageal cancer?
Disease control Recruiting nowThis phase 2 trial tests whether obeticholic acid can reduce damage from bile acids in people with Barrett's esophagus, a condition that can lead to esophageal cancer. About 30 adults with Barrett's esophagus will take the drug or a placebo for 6 months. Researchers will measure …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for liver cancer: Triple-Drug cocktail enters Mid-Stage trial
Disease control Recruiting nowThis phase 2 trial tests whether adding lenvatinib to the STRIDE regimen (durvalumab plus tremelimumab) works better than STRIDE alone for people with advanced liver cancer that cannot be surgically removed. About 140 adults who have not had prior systemic therapy will be enrolle…
Phase: PHASE2 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a modified stomach bypass speed up recovery in advanced gastric cancer?
Disease control Recruiting nowThis trial compares two surgical bypass procedures for people with advanced stomach cancer that blocks the passage of food. The standard approach connects the stomach directly to the small intestine, while the experimental approach adds a partial partition of the stomach to reduc…
Phase: NA • Sponsor: Gyeongsang National University Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New pill targets stubborn colorectal cancer mutation
Disease control Recruiting nowThis study tests an experimental pill called VS-7375, designed to block a specific cancer-driving protein (KRAS G12D). The trial includes people with metastatic colorectal cancer that has this mutation. Some participants receive VS-7375 alone, others get it combined with an antib…
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New radioactive 'Smart Bomb' targets Hard-to-Treat cancers
Disease control Recruiting nowThis study is testing a new way to find and treat several types of advanced solid tumors, including kidney, pancreatic, and colorectal cancers. It uses a special radioactive compound that attaches to a protein found on these cancer cells. The study has multiple parts: first, to s…
Phase: PHASE1, PHASE2 • Sponsor: Lumara Bio Oncologics GmbH • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New injection shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new drug called JL19001 in people with advanced solid tumors or a type of lymphoma that has come back or not responded to treatment. The main goal is to find a safe dose and check for side effects. About 14 participants will receive the drug as a sh…
Phase: PHASE1 • Sponsor: Jecho Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a Two-Drug combo reawaken the immune system against resistant cancers?
Disease control Recruiting nowThis trial tests whether combining bexmarilimab with nivolumab can help people whose cancers no longer respond to immunotherapy. It focuses on two cancers: non-small cell lung cancer and melanoma. The study first finds the safest dose of bexmarilimab to give with a fixed dose of …
Phase: PHASE1, PHASE2 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can adding a fourth drug shrink large liver tumors that invade the portal vein?
Disease control Recruiting nowThis trial is testing whether adding hepatic arterial infusion chemotherapy (HAIC) to a combination of lenvatinib, sintilimab, and drug-eluting bead chemoembolization (DEB-TACE) can better control large liver cancers (over 7 cm) that have spread into the portal vein. About 320 pa…
Phase: PHASE2 • Sponsor: Second Affiliated Hospital of Guangzhou Medical University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New chemo sequence aims to make pancreatic tumors operable
Disease control Recruiting nowThis phase 2 trial is testing whether giving two different chemotherapy regimens one after the other can shrink pancreatic tumors that are borderline or locally advanced, making them easier to remove surgically. The study enrolls 64 adults with pancreatic adenocarcinoma. Particip…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers by homing in on a specific protein
Disease control Recruiting nowThis study tests an experimental drug called SG1906 in people with advanced solid tumors that have a specific protein (CLDN18.2) on their surface. The trial has two parts: first, finding the safest dose, and then checking for early signs that the drug can shrink tumors. About 60 …
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug cocktail targets metastatic colorectal cancer in early trial
Disease control Recruiting nowThis early-phase trial is testing whether adding an experimental drug called CA-4948 to standard chemotherapy (FOLFOX) and a targeted therapy (bevacizumab) is safe for people with metastatic colorectal cancer. About 24 adults whose cancer has spread and cannot be surgically remov…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug MGC026 takes on advanced cancers in first human trial
Disease control Recruiting nowThis early-phase trial tests MGC026, a biologic drug given by IV, in 250 adults with advanced solid tumors that have not responded to standard treatments. The study has two parts: first, finding a safe dose, then expanding to see if the drug shrinks tumors. Participants receive u…
Phase: PHASE1 • Sponsor: MacroGenics • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Shielding immune cells during radiation: a new strategy against esophageal cancer?
Disease control Recruiting nowThis trial is testing whether a special radiation technique, called lymphocyte-sparing radiotherapy, can reduce the drop in immune cells (lymphocytes) that often happens during standard chemoradiation for esophageal cancer. The study will compare this new approach to conventional…
Phase: NA • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for pancreatic cancer: targeted drug may delay return in BRCA patients
Disease control Recruiting nowThis phase II trial is testing whether the drug olaparib can help prevent pancreatic cancer from coming back in people who have already had surgery and chemotherapy and carry a BRCA1, BRCA2, or PALB2 mutation. Olaparib is a targeted therapy that blocks a repair enzyme cancer cell…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Blood test may spare throat cancer patients from full radiation
Disease control Recruiting nowThis trial is testing whether a blood test that detects HPV DNA can help doctors safely reduce the amount of radiation given after surgery for HPV-positive throat cancer. After surgery, patients with undetectable HPV DNA in their blood may receive a lower dose of radiation, while…
Phase: NA • Sponsor: Indiana University • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a Two-Drug attack shrink Hard-to-Treat colorectal tumors?
Disease control Recruiting nowThis phase 3 trial is testing whether an experimental immunotherapy called IBI363, combined with the anti-angiogenic drug bevacizumab, can help people with advanced colorectal cancer that has stopped responding to standard treatments. About 550 adults whose cancer has progressed …
Phase: PHASE3 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a chemo boost outsmart lingering colon cancer cells?
Disease control Recruiting nowThis trial is testing whether giving a stronger chemotherapy regimen (mFOLFIRINOX) early can improve outcomes for people with stage II-III colon cancer who still have signs of cancer DNA in their blood during standard adjuvant chemo. Participants are randomly assigned to either r…
Phase: PHASE3 • Sponsor: Seoul National University Hospital • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Roche offers lifeline: continued cancer drug access for trial patients
Disease control Recruiting nowThis study gives people with cancer continued access to an experimental Roche treatment they were already receiving in a previous trial. It is for patients who still need the drug and cannot get it locally. The goal is to keep providing the treatment and monitor any side effects.
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for rare cancers: drug combo trial launches
Disease control Recruiting nowThis study tests a combination of two drugs, nilotinib (a pill) and paclitaxel (given by IV), for people with rare advanced cancers that have not responded to standard treatments. The goal is to see if the drugs can shrink or stop tumor growth. About 82 adults with specific rare …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Double immunotherapy may keep nasopharyngeal cancer at bay
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug relatlimab to standard nivolumab maintenance therapy can extend the time before cancer grows or spreads in patients with recurrent or metastatic nasopharyngeal cancer linked to Epstein-Barr virus. Participants first …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Belzutifan extension trial aims to extend lives in VHL and advanced cancer
Disease control Recruiting nowThis extension study follows people with von Hippel-Lindau (VHL) disease or advanced solid tumors who are already taking belzutifan in another trial. The goal is to see how long they live and how safe the drug is over the long term. About 450 participants will take belzutifan by …
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
MRNA cancer shots: new hope or hype?
Disease control Recruiting nowThis early-stage trial tests two experimental mRNA therapies (mRNA-4106 and mRNA-4200) in 42 people with advanced solid tumors like melanoma, lung, or liver cancer. Some participants receive the mRNA therapy alone, others get it combined with the immunotherapy drug pembrolizumab.…
Phase: PHASE1 • Sponsor: ModernaTX, Inc. • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental injection targets tumors directly in new cancer trial
Disease control Recruiting nowThis early-phase study tests an experimental drug called VAX014, which is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The study will first find a safe dose of VAX014 alone, then te…
Phase: PHASE1 • Sponsor: Vaxiion Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New combo therapy aims to freeze and burn liver cancer
Disease control Recruiting nowThis study tests a device that uses both freezing and heating to destroy liver tumors in people with liver cancer or colorectal cancer that has spread to the liver. The goal is to see if this approach improves how long patients live without their cancer growing, and whether it ac…
Phase: NA • Sponsor: Fudan University • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in large trial
Disease control Recruiting nowThis phase 2 trial is testing an experimental drug called patritumab deruxtecan (HER3-DXd) in 740 people with advanced solid tumors, including melanoma, lung, breast, and other cancers. The drug is given by IV every three weeks. The main goal is to see if the drug shrinks tumors.…
Phase: PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can precision protons spare rectal cancer patients from harsh side effects?
Disease control Recruiting nowThis trial is testing whether proton beam radiation, a more precise form of radiation, causes fewer stomach and bowel side effects than standard photon radiation when given before surgery for high-risk rectal cancer. About 254 patients will be randomly assigned to receive either …
Phase: NA • Sponsor: Alexander Valdman • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill SHY-ONC6 takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called SHY-ONC6 in people with advanced or metastatic solid tumors (including breast, colon, lung, pancreatic, and others) that have stopped responding to standard treatments. The study aims to find a safe dose and check for …
Phase: PHASE1 • Sponsor: SHY Therapeutics • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
A new radiation combo may spare the rectum in early cancer
Disease control Recruiting nowThis trial tests whether a combination of contact X-ray brachytherapy and short-course radiotherapy can preserve the rectum in people with early-stage rectal cancer. Participants receive this experimental radiation regimen, with some also getting chemotherapy. The goal is to see …
Phase: NA • Sponsor: Alexander Valdman • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New shot could make cancer treatment easier for patients with advanced tumors
Disease control Recruiting nowThis study tests a new way to give the drug rilvegostomig as a shot under the skin instead of through an IV. It is for adults with advanced solid tumors who have already tried standard treatments. The goal is to find a dose that works as well as the IV version and to check for si…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Experimental pill GS-1206 takes aim at Hard-to-Treat solid tumors
Disease control Recruiting nowThis study tests an experimental oral drug called GS-1206 in adults with advanced or metastatic solid tumors that have a specific genetic mutation. The main goals are to evaluate the drug's safety, tolerability, and how the body processes it. Participants must have tumors that ha…
Phase: PHASE1 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug DS1025a takes on advanced solid tumors in first human trial
Disease control Recruiting nowThis trial is testing a new drug called DS1025a in people with advanced solid tumors that have spread, cannot be removed by surgery, or have stopped responding to other treatments. The main goals are to check the drug's safety, how the body processes it, and whether it shows any …
Phase: PHASE1 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New pill takes on Hard-to-Treat KRAS cancers
Disease control Recruiting nowThis study tests an experimental drug called BLU-924 (SAR449336) in people with advanced pancreatic, lung, or colorectal cancers that have specific KRAS mutations. The drug is designed to block the cancer-driving KRAS protein. The trial will enroll about 265 participants to evalu…
Phase: PHASE1, PHASE2 • Sponsor: Blueprint Medicines Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New hope for stomach cancer: enhertu combo takes on tough tumors
Disease control Recruiting nowThis large Phase 3 trial is testing whether a newer targeted drug, trastuzumab deruxtecan (Enhertu), combined with chemotherapy and possibly the immunotherapy pembrolizumab (Keytruda), works better than the current standard treatment for advanced HER2-positive stomach or gastroes…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Electromagnetic fields join the fight against pancreatic cancer
Disease control Recruiting nowThis study tests whether adding a device that delivers amplitude-modulated radiofrequency electromagnetic fields (Therabionic P1) to standard chemotherapy (gemcitabine and nab-paclitaxel) can help control metastatic pancreatic cancer. About 30 adults with advanced pancreatic canc…
Phase: PHASE2 • Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New cancer drug MBS8(1V270) enters first human trials
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called MBS8(1V270), given alone or with the immunotherapy pembrolizumab, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and find the right dose. About 1…
Phase: PHASE1 • Sponsor: MonTa Biosciences ApS • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Stomach cancer patients may soon get immunotherapy as a simple shot instead of an IV drip
Disease control Recruiting nowThis phase 3 trial compares a subcutaneous (under-the-skin) injection of tislelizumab to the standard intravenous (IV) infusion, both given with chemotherapy, as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery or has sp…
Phase: PHASE3 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat breast cancers
Disease control Recruiting nowThis early-stage study tests a new drug called LOXO-783 in people with advanced breast cancer or other solid tumors that have a specific change in the PIK3CA gene. The main goals are to find the safest dose and check for side effects. About 193 participants will take the drug alo…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Could a simple asthma drug prevent a dangerous immunotherapy side effect?
Disease control Recruiting nowThis study tests whether using inhaled budesonide (a steroid commonly used for asthma) for one year can stop lung inflammation from coming back in cancer patients who had a serious immune reaction to immunotherapy. About 94 adults with solid tumors who recently had lung inflammat…
Phase: PHASE2 • Sponsor: AHS Cancer Control Alberta • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for stomach cancer: experimental drug combo trial opens
Disease control Recruiting nowThis study tests new experimental drugs combined with standard chemotherapy and immunotherapy for people with advanced stomach, gastroesophageal junction, or esophageal cancer that cannot be removed by surgery or has spread. About 160 participants will receive the combination to …
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Experimental drug DM005 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called DM005 in 136 people with advanced solid tumors, including lung, head and neck, and other cancers that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and se…
Phase: PHASE1, PHASE2 • Sponsor: Doma Biopharmaceutical(Suzhou)Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New Triple-Action antibody takes on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-T187, a special antibody that targets two proteins (EGFR and MET) on cancer cells. It is given alone or with other drugs to people with advanced solid tumors that have spread or cannot be removed. The main goals are to check safet…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New hope for kids with tough cancers: GAIA-102 trial launches
Disease control Recruiting nowThis early-stage trial tests a new drug called GAIA-102 in children whose neuroblastoma or other solid tumors have not responded to standard treatments. The study has four groups, testing GAIA-102 alone or combined with other cancer drugs. The main goal is to check safety and fin…
Phase: PHASE1 • Sponsor: Kyushu University • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New master trial aims to speed up cancer treatments for kids
Disease control Recruiting nowThis trial tests several cancer drugs in children and young adults with solid tumors. It uses a master protocol to test different drug combinations more efficiently. About 105 participants will receive one of eight drugs, including ramucirumab, cyclophosphamide, and others. The g…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can stomach cancer surgery also tame diabetes?
Disease control Recruiting nowThis trial tests three different ways to reconnect the digestive tract after stomach cancer surgery to see which one best controls blood sugar in people who also have type 2 diabetes. Participants will be randomly assigned to one of three surgical procedures. The main goal is to …
Phase: NA • Sponsor: Korea University Anam Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug shows promise for Hard-to-Treat GI cancers
Disease control Recruiting nowThis study is testing a drug called patritumab deruxtecan in people with advanced gastrointestinal cancers that have spread. The drug is given through a vein and aims to shrink tumors. The trial will check how safe the drug is and how many people's cancers respond to treatment. A…
Phase: PHASE1, PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Custom-Made immune cell vaccine turn the tide against solid tumors?
Disease control Recruiting nowThis trial tests a personalized approach to treating advanced solid tumors. Doctors take a patient's own immune cells, train them to recognize that patient's specific cancer mutations, and inject them back under the skin. The goal is to see if these customized cells can safely tr…
Phase: NA • Sponsor: ZSky Biotech Inc • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Exercise as medicine: tailored workouts may rebuild strength after cancer
Disease control Recruiting nowThis trial tests whether a personalized exercise program can safely help cancer survivors improve their physical fitness and quality of life. Participants who have finished curative treatment at least two months ago will receive a tailored plan based on heart, lung, and muscle as…
Phase: NA • Sponsor: Kaohsiung Medical University Chung-Ho Memorial Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New combo aims to shrink rectal tumors without surgery
Disease control Recruiting nowThis phase 2 trial tests a new approach for patients with a specific type of mid-low rectal cancer (pMMR/MSS). Participants receive a short course of radiation followed by six cycles of the immunotherapy drug ivonescimab. The goal is to see if this combination can make the cancer…
Phase: PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
Can a Triple-Drug combo erase rectal tumors before surgery?
Disease control Recruiting nowThis phase II trial is testing whether giving a combination of two immunotherapies (sintilimab and IBI-310) along with chemotherapy before surgery can improve outcomes for people with a specific type of locally advanced rectal cancer (MSI-H/dMMR). The main goal is to see how ofte…
Phase: PHASE2 • Sponsor: Xijing Hospital • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug STRO-004 takes on advanced cancers in early trial
Disease control Recruiting nowThis early-phase study tests a new drug called STRO-004 in adults with advanced solid tumors that have not responded to standard treatments. The study has three parts: finding a safe dose of STRO-004 alone, testing that dose in more patients, and combining STRO-004 with another d…
Phase: PHASE1 • Sponsor: Sutro Biopharma, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug PHN-012 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called PHN-012 in people with advanced colon, pancreatic, or lung cancer that has stopped responding to standard treatments. The drug is an antibody-drug conjugate, designed to deliver a powerful cancer-killing agent directly to tumor cells…
Phase: PHASE1 • Sponsor: Pheon Therapeutics • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radioactive drug targets FAP-Positive tumors in early trial
Disease control Recruiting nowThis early-phase study tests a new radioactive drug, LY4337713, in people with advanced cancers that have high levels of a protein called FAP. The cancers include certain types of ovarian, breast, pancreatic, colorectal, esophageal, stomach, and bile duct cancers. The study aims …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can a new pill help the immune system fight cancer?
Disease control Recruiting nowThis trial is testing an investigational drug called ARV-6723, given as a pill, in people with advanced solid tumors. The drug is designed to help the immune system recognize and attack cancer cells. The study will test ARV-6723 alone and in combination with pembrolizumab, an imm…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug EVOLVE104 takes on tough cancers in early human trial
Disease control Recruiting nowThis early-stage trial is testing an experimental drug called EVOLVE104 in people with advanced bladder cancer or several types of squamous cell carcinoma (lung, esophagus, skin, and others). The study aims to find a safe dose and see if the drug can shrink tumors. It is for pati…
Phase: PHASE1 • Sponsor: EvolveImmune United, Inc • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Engineered immune cells take aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage study tests a new treatment called NT-175 for people with advanced solid tumors (like lung, colon, or breast cancer) that have a specific mutation (TP53 R175H) and a certain immune marker (HLA-A*02:01). NT-175 is made from a patient's own immune cells, which are …
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Could a simple antibiotic course fight oral cancer from the inside?
Disease control Recruiting nowThis study is testing whether taking the antibiotic metronidazole and using a chlorhexidine mouth rinse for 10 days before surgery can lower the amount of bacteria living inside oral cancer tumors. The researchers will compare bacteria levels before and after treatment in 30 adul…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for hard-to-treat colon cancer? phase 3 trial launches
Disease control Recruiting nowThis study tests whether adding the experimental drug INCA33890 to standard chemotherapy and bevacizumab helps people with metastatic colorectal cancer that is microsatellite stable (a type that doesn't respond well to immunotherapy). About 700 adults who have not had prior treat…
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for cancer patients: experimental drug aims to stop dangerous blood clots
Disease control Recruiting nowThis study tests an experimental drug, REGN7508, to see if it works better than the standard blood thinner apixaban for treating and preventing blood clots in people with cancer. The trial will include about 1,600 participants with or without cancer who have deep vein thrombosis …
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New cell therapy targets common cancer mutation in early trial
Disease control Recruiting nowThis early-phase trial tests a new type of cell therapy called TCR1188-ABC for people with certain advanced cancers (pancreatic, colorectal, lung, or bile duct) that have a specific KRAS G12V mutation. The treatment involves taking a patient's own immune cells, engineering them t…
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New pill combo aims to shrink Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis study tests an experimental oral drug called zongertinib, which blocks HER2, a protein that fuels cancer growth. It is given alone or with other cancer drugs to adults with advanced HER2+ breast, stomach, or colorectal cancer that has spread and not responded to prior treatm…
Phase: PHASE1, PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug called BG-C0979, alone or with another drug (tislelizumab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see if the drug shrinks tumors. Ab…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New radiation drug targets Hard-to-Treat cancers
Disease control Recruiting nowThis study tests a new drug, LY4257496, that delivers radiation directly to cancer cells with a specific protein (GRPR). It is for adults with advanced solid tumors like breast, prostate, or colorectal cancer that have not responded to other treatments. The goal is to see if the …
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for pancreatic cancer: targeted pill plus chemotherapy in Late-Stage trial
Disease control Recruiting nowThis Phase 3 trial is testing whether adding a new targeted pill (INCB161734) to standard chemotherapy helps people with a specific type of advanced pancreatic cancer (KRAS G12D mutation) live longer. About 588 participants who have not had prior treatment for metastatic disease …
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Can an mRNA therapy supercharge the immune system against cancer?
Disease control Recruiting nowThis trial is testing an experimental therapy called STX-003, which uses mRNA to produce a protein that may help the immune system fight cancer. It is given intravenously, either alone or with the immunotherapy drug pembrolizumab (Keytruda). The study involves adults with advance…
Phase: PHASE1, PHASE2 • Sponsor: Strand Therapeutics Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New chemo combo shows promise for tough pancreatic tumors
Disease control Recruiting nowThis study tests a new way of giving chemotherapy to people with pancreatic cancer that is on the edge of being removable. The goal is to shrink the tumor enough for successful surgery. About 35 adults will receive two different chemo drug combinations in alternating cycles. The …
Phase: PHASE2 • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Stomach cancer trial combines chemo with Bacteria-Fighting treatment
Disease control Recruiting nowThis study is for people with a type of stomach cancer that is H. pylori-positive and can be removed with surgery. It compares standard chemotherapy before and after surgery to the same chemotherapy plus treatment to eliminate H. pylori bacteria. The goal is to see if adding the …
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy targets Hard-to-Treat HER2 cancers
Disease control Recruiting nowThis early-phase trial tests the safety and best dose of two drugs—neratinib and trastuzumab deruxtecan—given together to people with advanced solid tumors that have HER2 gene changes. The goal is to see if the combination can shrink tumors that have spread or can't be removed by…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New drug targets 13 cancers in major trial
Disease control Recruiting nowThis study tests a drug called ifinatamab deruxtecan (I-DXd) in people with 13 types of advanced solid tumors that have come back or spread. The trial aims to see how well the drug shrinks tumors and what side effects it causes. About 520 participants will receive the drug intrav…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Engineered immune cells take on Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new treatment called GC203 TIL, which uses a patient's own immune cells that are modified in a lab to better fight cancer. It is for adults with advanced solid tumors that no longer respond to standard therapies. The main goal is to check safety, an…
Phase: PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug cocktail aims to stop liver cancer from coming back after surgery
Disease control Recruiting nowThis phase 3 study tests whether giving two drugs (tislelizumab and lenvatinib) before surgery can help prevent liver cancer from returning in patients at high risk of recurrence. About 198 adults with early-stage liver cancer will be enrolled. The main goal is to see if this app…
Phase: PHASE3 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo aims to shrink hard-to-treat tumors
Disease control Recruiting nowThis study tests a new drug called zanzalintinib, alone or with other immune-boosting drugs, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find safe doses and see if the combination can shrink tumors or slow their growth.…
Phase: PHASE1 • Sponsor: Exelixis • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Zinc-Based compound fight cancer?
Disease control Recruiting nowThis trial tests an experimental drug called KLS-1, a form of zinc aspartate enriched with a specific zinc isotope, in adults with certain solid tumors (like melanoma, prostate, or pancreatic cancer) or chronic lymphocytic leukemia (CLL). The goal is to find the safest and most e…
Phase: PHASE1, PHASE2 • Sponsor: Vector Vitale LLC • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Blood test may tailor throat cancer treatment, sparing patients from harsh side effects
Disease control Recruiting nowThis trial tests whether a blood test that detects HPV DNA can help doctors personalize treatment for people with HPV-related throat cancer. Participants receive radiation therapy, with or without chemotherapy, but the intensity is adjusted based on their blood test results and c…
Phase: PHASE2 • Sponsor: Jonathan Schoenfeld, MD, MPH • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New chemo combo tested to extend life in Hard-to-Treat stomach and esophageal cancers
Disease control Recruiting nowThis study tests whether a stronger chemotherapy mix (mFOLFIRINOX) works better than the standard mix (FOLFOX) for people with advanced stomach, esophageal, or gastroesophageal junction cancer that cannot be removed by surgery. Some participants also receive the immunotherapy dru…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Immunotherapy before surgery: a new hope for HPV throat cancer?
Disease control Recruiting nowThis phase 2 trial is testing whether the immunotherapy drug atezolizumab, given before surgery, can help treat HPV-related throat cancer that can be removed. About 20 adults with stage I oropharyngeal cancer will receive two doses of atezolizumab followed by standard surgery. Th…
Phase: PHASE2 • Sponsor: Emory University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a double immunotherapy beat standard care for a tough stomach cancer?
Disease control Recruiting nowThis phase II trial is comparing a new combination of two immunotherapies (iparomlimab and tuvonralimab) against standard chemotherapy plus a PD-1/PD-L1 inhibitor as a first-line treatment for people with recurrent or metastatic gastric cancer that is MSI-H or dMMR. The study aim…
Phase: PHASE2 • Sponsor: Peking University • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Blood test guides safer cancer treatment after surgery
Disease control Recruiting nowThis study tests whether a blood test that detects tumor DNA can help doctors choose the right amount of chemotherapy and radiation after surgery for HPV-positive throat cancer. The goal is to give less intense treatment to patients with a low risk of cancer returning, reducing s…
Phase: PHASE2 • Sponsor: Zachary Zumsteg • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Texts vs. manuals: new trial aims to help rural cancer survivors kick the habit
Disease control Recruiting nowThis study tests whether text-based support can help rural cancer survivors who smoke to quit. Participants will either receive text messages that gradually reduce cigarette use or a self-help manual. The goal is to see which approach works better for long-term smoking cessation.
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New combo therapy aims to outsmart resistant head and neck cancer
Disease control Recruiting nowThis study tests whether adding cetuximab to standard immunotherapy (pembrolizumab) helps people with advanced head and neck cancer that has stopped responding to platinum chemotherapy live longer. About 158 adults with cancer that has returned or spread will receive either pembr…
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New trial zaps spreading colon cancer with precision: could it be a Game-Changer?
Disease control Recruiting nowThis phase III trial is testing whether adding focused treatments—like high-dose radiation, surgery, or heat ablation—to standard chemotherapy can help people with colorectal cancer that has spread to up to four sites. The goal is to see if destroying those metastatic tumors impr…
Phase: PHASE3 • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Experimental drug plus radiation aims to tackle returning head and neck cancers
Disease control Recruiting nowThis early-phase trial is testing whether a drug called camonsertib, combined with a precise type of radiation, can help control head and neck cancers that have come back or cannot be removed by surgery. About 39 adults with these cancers will receive the drug along with focused …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a new immunotherapy combo shrink Hard-to-Treat tumors?
Disease control Recruiting nowThis early-stage trial is testing an experimental immunotherapy called AB122, given alone or combined with other investigational drugs, in people with advanced solid tumors such as pancreatic, colorectal, lung, and stomach cancers. The goal is to find out which combinations are s…
Phase: PHASE1 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Supercharged immune cells take on tough pancreatic cancer
Disease control Recruiting nowThis early-phase trial tests a new therapy called GC203 TIL, which uses a patient's own immune cells that are genetically modified to better attack pancreatic cancer. Ten adults whose cancer has not responded to standard treatments will receive these cells after a short course of…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a Patient's own immune cells fight advanced cancer?
Disease control Recruiting nowThis trial investigates whether tumor-infiltrating lymphocytes (TILs) — immune cells taken from a patient's own tumor — can be expanded in the lab and infused back to attack cancer. It enrolls adults aged 18 to 75 with advanced solid tumors who have failed standard treatments. Th…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could your own tumor cells fight your cancer? early trial begins
Disease control Recruiting nowThis early-phase trial tests a personalized therapy for people with advanced solid tumors that have not responded to standard treatments. Doctors take immune cells from a sample of the patient's tumor, grow them into large numbers in a lab, and infuse them back into the patient. …
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers with genetic weakness
Disease control Recruiting nowThis early-stage trial is testing a new drug called IDE892, alone or with another drug (IDE397), in people with advanced solid tumors that have a specific genetic deletion (MTAP). The study aims to find safe doses and see if the drugs shrink tumors. It includes 260 adults with ca…
Phase: PHASE1 • Sponsor: IDEAYA Biosciences • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Immune cells from your own tumor could fight stomach and bowel cancers
Disease control Recruiting nowThis early-phase study tests a personalized cell therapy for people with advanced gastrointestinal tumors that have not responded to standard treatments. Doctors take immune cells from the patient's own tumor, grow them in a lab, and infuse them back after a short chemotherapy pr…
Phase: EARLY_PHASE1 • Sponsor: Shanghai Juncell Therapeutics • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Cancer-Killing virus trial launches for patients out of options
Disease control Recruiting nowThis Phase 1 trial tests IDOV-Immune, a genetically engineered virus designed to infect and destroy cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatme…
Phase: PHASE1 • Sponsor: ViroMissile, Inc. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Immunotherapy plus chemotherapy before surgery shows promise against tough stomach cancers
Disease control Recruiting nowThis trial investigates whether adding the immunotherapy drug serplulimab (HLX10) to standard chemotherapy (S-1 and oxaliplatin) before and after surgery can improve outcomes for people with locally advanced, PD-L1-positive stomach or gastroesophageal junction cancer. Participant…
Phase: PHASE2 • Sponsor: National Cancer Center, Japan • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug targets tough cancers with KRAS G12D mutation
Disease control Recruiting nowThis study tests a new drug called ASP3082 in 60 people with advanced lung or pancreatic cancer that has a specific gene change (KRAS G12D). Participants receive the drug intravenously once a week in 21-day cycles. The main goal is to see how well the drug shrinks tumors and to u…
Phase: PHASE2 • Sponsor: Gustave Roussy, Cancer Campus, Grand Paris • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Liver pump chemotherapy may boost survival in advanced colorectal cancer
Disease control Recruiting nowThis phase 3 trial is testing whether adding a chemotherapy pump that delivers drugs directly to the liver (hepatic arterial infusion, or HAI) can help people with colorectal cancer that has spread to the liver and cannot be removed by surgery. About 408 participants will receive…
Phase: PHASE3 • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Less neck surgery may be just as effective for oral cancer with one affected node
Disease control Recruiting nowThis trial tests whether removing fewer lymph nodes from the neck (selective dissection, levels I-IV) works as well as the standard more extensive removal (modified dissection, levels I-V) in people with oral cancer that has spread to a single lymph node. The goal is to see if th…
Phase: NA • Sponsor: Kolhapur Cancer Centre - Cancer Centers of America • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug combo aims to boost immune system against advanced cancers
Disease control Recruiting nowThis study tests a new drug, BI 1703880, combined with ezabenlimab in adults with advanced solid tumors that haven't responded to other treatments. The main goal is to find a safe dose of BI 1703880. Participants receive both drugs as infusions, with BI 1703880 given weekly then …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Robotic surgery breakthrough: single-port approach tested for stomach cancer
Disease control Recruiting nowThis early-stage study tests a new robotic surgery method that uses only one small incision to remove stomach cancer. The goal is to see if it is safe and works well. Twenty adults with stomach cancer will take part, and doctors will watch for complications during and up to 30 da…
Phase: NA • Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New drug FS-8002 enters human trials for Hard-to-Treat cancers
Disease control Recruiting nowThis early-stage trial is testing a new drug called FS-8002, alone or combined with other treatments, in 66 people with advanced solid tumors that have stopped responding to standard care. The main goals are to check safety, find the right dose, and get a first look at whether th…
Phase: PHASE1 • Sponsor: Shanghai Pushi Medical Science Co. Ltd • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Blood test may guide chemo choices for colon cancer patients
Disease control Recruiting nowThis study is for people with stage III colon cancer who have had surgery. It uses a blood test called Signatera to look for leftover cancer DNA. Depending on the results, patients get either immediate or delayed chemotherapy, and the type and length of chemo are tailored to thei…
Phase: PHASE2, PHASE3 • Sponsor: NRG Oncology • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody GEN1079 enters first human tests for advanced cancers
Disease control Recruiting nowThis early-stage trial is testing a new antibody called GEN1079 in people with certain advanced solid tumors. The study has three parts: first, finding a safe dose; then refining the dose; and finally, checking if the drug shrinks tumors. About 121 participants will receive the a…
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New triple therapy aims to stop pancreatic Cancer's return after surgery
Disease control Recruiting nowThis Phase 2 trial tests whether adding a personalized cancer vaccine (autogene cevumeran) and an immunotherapy drug (atezolizumab) to standard chemotherapy (mFOLFIRINOX) can keep pancreatic cancer from coming back after surgery. About 260 people whose tumors were completely remo…
Phase: PHASE2 • Sponsor: Genentech, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for tough esophageal cancer: experimental drug takes on chemo in major trial
Disease control Recruiting nowThis study tests a new drug called ifinatamab deruxtecan (I-DXd) in people with advanced esophageal cancer that has worsened after standard treatments like platinum chemotherapy and immunotherapy. About 510 adults will be randomly assigned to receive either I-DXd or a standard ch…
Phase: PHASE3 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can a smaller incision offer the same cancer surgery outcome?
Disease control Recruiting nowThis trial compares two surgical techniques for removing tumors near the pancreas (non-pancreatic periampullary adenocarcinomas). One method uses a single small incision plus one extra port, while the other uses the conventional five-port approach. The study will enroll 232 adult…
Phase: NA • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to outsmart advanced liver cancer
Disease control Recruiting nowThis phase II trial tests whether adding the immunotherapy drug atezolizumab to a targeted therapy (cabozantinib or lenvatinib) works better than the targeted therapy alone for people with advanced liver cancer that cannot be surgically removed. The study enrolls 122 adults whose…
Phase: PHASE2 • Sponsor: Academic and Community Cancer Research United • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Less may be more: testing a gentler neck dissection for oral cancer
Disease control Recruiting nowThis trial compares two types of neck surgery for people with oral cancer that has not spread to lymph nodes. One surgery removes lymph nodes from levels I to IV, while the other removes only levels I to III. The goal is to see whether the less extensive surgery can control cance…
Phase: NA • Sponsor: Kolhapur Cancer Centre - Cancer Centers of America • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could a Two-Drug punch before surgery shrink head & neck tumors?
Disease control Recruiting nowThis study tests whether adding an experimental drug (CDX-1140) to a standard immunotherapy (cemiplimab) before surgery can shrink advanced head and neck cancers more than the immunotherapy alone. About 44 people with stage III-IV head and neck cancer will receive either the comb…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Can adding immunotherapy to chemotherapy shrink pancreatic tumors before surgery?
Disease control Recruiting nowThis phase II trial is testing whether giving the immunotherapy drug pembrolizumab (Keytruda) along with standard FOLFIRINOX chemotherapy before surgery can help shrink tumors in people with resectable pancreatic cancer. The study enrolls adults with localized, potentially resect…
Phase: PHASE2 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for stomach and bowel cancers: experimental drug Rina-S enters Mid-Stage trial
Disease control Recruiting nowThis Phase 2 trial is testing a new drug called Rina-S (rinatabart sesutecan) in about 160 people with advanced gastrointestinal cancers that have spread or cannot be removed. The drug is given alone through an IV, and everyone receives it—no placebo. The study will check if the …
Phase: PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill targets HER2 cancers in phase 2 trial
Disease control Recruiting nowThis study tests an oral drug called zongertinib in adults with advanced solid tumors that have HER2 mutations or overexpression and have not responded to prior treatment. Participants take one of two daily doses and continue as long as they benefit. Doctors regularly check tumor…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New combo therapy aims to shrink Hard-to-Treat tumors
Disease control Recruiting nowThis early-stage trial tests a new drug called EVM14, given alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have spread or come back. The main goals are to check safety, find the right dose, and see if the drug helps control the cancer. A…
Phase: PHASE1, PHASE2 • Sponsor: Everest Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Could less be more? new study tests lower doses of cancer drug
Disease control Recruiting nowThis study is testing whether giving lower, less frequent doses of the cancer drug atezolizumab can still keep enough drug in the blood to fight cancer. About 30 adults with certain advanced cancers (like lung cancer or melanoma) will start with standard doses, then switch to a l…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can radiation plus immunotherapy make colon tumors disappear before surgery?
Disease control Recruiting nowThis trial is testing whether adding radiotherapy and immunotherapy to standard chemotherapy can shrink advanced colon tumors more effectively than chemotherapy alone. Adults with a specific type of stage T4M0 colon cancer will receive either the combination or chemotherapy only,…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New chemo mist targets abdominal cancer with fewer side effects
Disease control Recruiting nowThis early-stage trial tests a technique called PIPAC, which turns chemotherapy into a fine mist and sprays it directly into the abdomen during a keyhole surgery. The goal is to see if this method is safe and reduces side effects for people with biliary tract cancer that has spre…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can three common drugs boost chemotherapy against pancreatic cancer?
Disease control Recruiting nowThis pilot trial is testing whether adding a combination of three widely used drugs—metformin, digoxin, and simvastatin (called C3)—to standard chemotherapy (gemcitabine) can safely help people with advanced pancreatic cancer that has not responded to prior treatment. The study w…
Phase: PHASE1, PHASE2 • Sponsor: State University of New York - Downstate Medical Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Radiation plus immunotherapy may make inoperable liver cancer removable
Disease control Recruiting nowThis phase 2 trial tests whether adding radiotherapy to a combination of two drugs (QL1706 and bevacizumab) can shrink liver tumors that cannot currently be removed by surgery. The goal is to make enough tumors shrink so they can be surgically removed. The study will enroll 60 ad…
Phase: PHASE2 • Sponsor: Hebei Medical University Fourth Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for tumors that beat immunotherapy? early trial launches
Disease control Recruiting nowThis early-phase study tests a new drug (PLN-101095) alone or with pembrolizumab in adults whose advanced solid tumors have stopped responding to standard immunotherapy. About 124 participants will receive the treatment to check safety and early signs of tumor shrinkage. The goal…
Phase: PHASE1 • Sponsor: Pliant Therapeutics, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Tailor-Made vaccine aims to train immune system against cancer
Disease control Recruiting nowThis early-phase trial is testing a personalized cancer vaccine (ABO2109) combined with an immunotherapy drug (toripalimab) in people with solid tumors. The vaccine is custom-made for each patient to target their specific cancer. The study aims to check the safety of this combina…
Phase: EARLY_PHASE1 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo targets hard-to-treat cancers with KRAS mutation
Disease control Recruiting nowThis study tests two experimental drugs, elironrasib and daraxonrasib, given alone or together, in people with advanced solid tumors that have a specific KRAS G12C mutation. The goal is to see if the drugs are safe and can shrink or control the cancer. About 534 adults with lung,…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug BG-C477 enters human testing for Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase study tests a new drug, BG-C477, in about 310 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the best dose, and see if it can shrink tumors. The study is open-label, meaning ev…
Phase: PHASE1 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for hard-to-treat pancreatic cancer: targeted drug combo enters phase 3 trial
Disease control Recruiting nowThis study tests whether adding an experimental drug called zoldonrasib to standard chemotherapy helps people with a specific genetic form of metastatic pancreatic cancer (KRAS G12D mutation) live longer without their cancer growing. About 670 adults with advanced pancreatic canc…
Phase: PHASE3 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for stomach and bowel cancers? experimental drug enters human trials
Disease control Recruiting nowThis study tests an experimental drug called GSK5764227, given alone or with other treatments, in 320 people with advanced gastrointestinal cancers that have not responded to prior therapy. The main goal is to see if the drug can shrink tumors and how safe it is. It is an early-s…
Phase: PHASE1, PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug MK-4884 tested for safety in advanced cancers
Disease control Recruiting nowThis early-stage study tests a new drug called MK-4884 in about 120 people with advanced or metastatic solid tumors (colorectal, kidney, lung, or bile duct cancer). The main goal is to check the drug's safety and find the right dose. Researchers will monitor side effects and how …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo therapy targets Hard-to-Treat RAS-Mutant cancers
Disease control Recruiting nowThis study tests whether combining experimental RAS(ON) inhibitors with ivonescimab (an immunotherapy) can shrink or control advanced solid tumors that have a RAS mutation. About 370 adults with cancers like non-small cell lung cancer or colorectal cancer will receive these drugs…
Phase: PHASE1, PHASE2 • Sponsor: Revolution Medicines, Inc. • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Aiming to spare the neck: could smarter radiation cut side effects in oral cancer?
Disease control Recruiting nowThis phase II trial is testing whether a sentinel lymph node biopsy can guide radiation therapy to only one side of the neck in people with oral cavity squamous cell carcinoma. Currently, standard treatment often involves radiating both sides of the neck, which can harm saliva pr…
Phase: PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can a pill boost the immune system to fight Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called OATD-02 in people with advanced or metastatic colorectal, ovarian, pancreatic, or renal cell cancer. The goal is to see if the drug is safe and whether it can help the immune system attack tumors by increasing arg…
Phase: PHASE1 • Sponsor: Molecure S.A. • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Can immunotherapy before or after chemoradiation beat esophageal cancer?
Disease control Recruiting nowThis trial is investigating the best time to give immunotherapy for people with advanced esophageal cancer that cannot be removed by surgery. Participants will receive either immunotherapy before chemoradiation or after, to see which sequence helps control the cancer longer. The …
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new targeted pill tame advanced cancers? a phase i trial seeks answers
Disease control Recruiting nowThis early-stage trial tests an experimental drug called TQB3107, taken as a tablet, in people with advanced malignant tumors. The goal is to find a safe dose and understand how the body processes the drug. TQB3107 is designed to block a specific target inside cancer cells, poten…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can zapping pancreatic tumors with heat before surgery boost Chemo's power?
Disease control Recruiting nowThis trial is testing whether combining standard chemotherapy with a procedure that uses heat to destroy cancer cells can shrink pancreatic tumors before surgery. The approach uses an endoscope guided by ultrasound to deliver radiofrequency ablation directly to the tumor. Researc…
Phase: PHASE2 • Sponsor: The University of Texas Health Science Center, Houston • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a Two-Target antibody shrink Hard-to-Treat cancers?
Disease control Recruiting nowThis trial is testing an experimental drug called petosemtamab (MCLA-158) in people with advanced solid tumors, including colorectal, head and neck, and lung cancers. The drug is a bispecific antibody designed to block two cancer-related proteins, EGFR and LGR5. Researchers want …
Phase: PHASE1, PHASE2 • Sponsor: Merus B.V. • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Can a new drug called ROSE12 help fight advanced solid tumors?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called ROSE12, alone or combined with other anti-tumor agents, in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to evaluate safety, determine the best dose, and look…
Phase: PHASE1 • Sponsor: Chugai Pharmaceutical • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
AI-Powered app aims to transform colorectal cancer recovery monitoring
Disease control Recruiting nowThis trial tests a digital platform that uses artificial intelligence to monitor colorectal cancer patients after surgery. Patients report symptoms through a mobile app, and the AI analyzes the data to flag issues with color-coded alerts. The goal is to see if this system boosts …
Phase: NA • Sponsor: RenJi Hospital • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
Can a new pill shrink Hard-to-Treat tumors? a trial aims to find out
Disease control Recruiting nowThis phase 3 trial is testing an experimental drug called VC004 in people aged 12 and older with advanced or metastatic solid tumors that cannot be removed by surgery. The goal is to see whether VC004 capsules can shrink tumors and control the disease. All participants receive th…
Phase: PHASE3 • Sponsor: Jiangsu vcare pharmaceutical technology co., LTD • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
A new care pathway aims to get cancer surgery patients home safer and faster
Disease control Recruiting nowThis large trial tests whether a structured program called RESET can improve outcomes for adults undergoing planned cancer surgery. RESET combines pre-surgery preparation (prehabilitation), enhanced in-hospital recovery practices, and personalized support after discharge. Researc…
Phase: NA • Sponsor: Regional Specialist Hospital in Wroclaw • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Virus therapy aims to boost chemo in tough pancreatic cancer
Disease control Recruiting nowThis trial tests whether a virus called VCN-01, given more frequently, is safe and tolerable when combined with standard chemotherapy (nab-paclitaxel and gemcitabine) for people with newly diagnosed stage IV pancreatic cancer that has spread. Participants receive up to three dose…
Phase: PHASE1, PHASE2 • Sponsor: Theriva Biologics SL • Aim: Disease control
Last updated Jul 29, 2026 00:00 UTC
-
Can a Two-Pronged attack shrink Hard-to-Treat colorectal tumors?
Disease control Recruiting nowThis phase II trial is testing whether combining two targeted drugs—fruquintinib, which blocks blood vessel growth to tumors, and cetuximab-beta, which blocks a cancer growth signal—can shrink tumors in people with RAS wild-type metastatic colorectal cancer who have already tried…
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a Four-Drug cocktail tame pancreatic cancer? a Real-World trial seeks answers
Disease control Recruiting nowThis study follows about 70 people with metastatic pancreatic cancer who are receiving NalIriFOx as their first treatment. Researchers are collecting real-world data to see how well the drug combination controls the disease and what side effects occur. The goal is to understand w…
Sponsor: Hellenic Cooperative Oncology Group • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can freezing tumors boost immunotherapy in hard-to-treat bile duct cancers?
Disease control Recruiting nowThis phase II trial is testing whether freezing tumors (cryoablation) before giving an experimental immunotherapy drug called rilafup α along with standard chemotherapy can help shrink or control advanced bile duct and gallbladder cancers. The study enrolls 30 people who have not…
Phase: PHASE2 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Could an AI-Designed pill take on Hard-to-Treat cancers?
Disease control Recruiting nowThis early-stage trial is testing an experimental oral drug called ISM8207 in people with advanced solid tumors or relapsed/refractory B-cell lymphoma who have no standard treatment options left. The main goals are to check the drug's safety, tolerability, and how the body proces…
Phase: PHASE1 • Sponsor: InSilico Medicine Hong Kong Limited • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
New drug combo aims to eliminate rectal tumors before surgery
Disease control Recruiting nowThis phase 2 trial tests whether adding a new form of chemotherapy (liposomal irinotecan) to standard radiotherapy, immunotherapy (tislelizumab), and another chemotherapy (capecitabine) can make advanced rectal cancers disappear before surgery. The study enrolls adults aged 18–75…
Phase: PHASE2 • Sponsor: Affiliated Cancer Hospital of Shantou University Medical College • Aim: Disease control
Last updated Jul 26, 2026 00:00 UTC
-
Can a new antibody help the immune system fight advanced cancers?
Disease control Recruiting nowThis early-phase trial is testing an experimental drug called M3T01, a monoclonal antibody that targets a protein called FasL, in people with advanced solid tumors that have spread or cannot be removed by surgery. The study aims to see if M3T01 is safe and tolerable when given al…
Phase: PHASE1 • Sponsor: Providence Health & Services • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a new Liposome-Wrapped drug shrink Hard-to-Treat solid tumors?
Disease control Recruiting nowThis trial is testing an experimental drug called AT-1965 in people with advanced solid tumors that have stopped responding to standard treatments. The study has two parts: first, finding a safe dose, and then seeing whether the drug can shrink tumors. About 100 participants will…
Phase: PHASE1, PHASE2 • Sponsor: Alyssum Therapeutics • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New biologic drug DBC-664 takes aim at Hard-to-Treat cancers
Disease control Recruiting nowThis early-phase trial is testing an experimental biologic drug, DBC-664, in adults with advanced solid tumors such as ovarian, lung, and stomach cancers that have spread or come back. The study has two parts: first, finding a safe dose, and then expanding to see how well the dru…
Phase: PHASE1 • Sponsor: Duboce Biopharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a Two-Pronged antibody boost chemo against Hard-to-Treat colorectal cancer?
Disease control Recruiting nowThis phase II trial is testing whether adding an experimental drug called PM8002 (pumitamig) to standard chemotherapy can shrink tumors in people with a common type of metastatic colorectal cancer that has not been treated before. PM8002 is a bispecific antibody designed to block…
Phase: PHASE2 • Sponsor: Biotheus Inc. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
Can a common muscle relaxant make radiation deadlier for rectal cancer?
Disease control Recruiting nowThis early-stage trial tests whether adding the drug papaverine to standard radiation therapy can safely improve treatment for locally advanced rectal cancer. Papaverine may help by reducing oxygen starvation inside tumors, which often makes radiation less effective. The study en…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can stronger radiation tame inoperable rectal cancer without surgery?
Disease control Recruiting nowThis trial investigates whether giving a higher dose of radiotherapy can safely control locally recurrent rectal cancer that cannot be surgically removed. Around 30 adults with this condition will receive either stereotactic body radiotherapy or hyperfractionated chemo-reirradiat…
Phase: NA • Sponsor: Heike M.U. Peulen • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a cholesterol drug help immunotherapy fight colorectal cancer?
Disease control Recruiting nowThis phase II trial is testing whether adding the immunotherapy drug adebrelimab and the cholesterol-lowering drug simvastatin to standard chemotherapy and targeted therapy can shrink tumors in people with advanced colorectal cancer that has not responded to prior treatment. The …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Experimental pill takes on Hard-to-Treat ovarian cancer
Disease control Recruiting nowThis early-stage trial tests an experimental oral drug called APG-2449, alone or combined with another cancer drug, in people with platinum-resistant recurrent ovarian cancer or other advanced solid tumors. The study aims to find safe doses and understand how the drug works in th…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could less be more? trial tests reduced radiation and chemo after surgery for HPV-Linked throat cancer
Disease control Recruiting nowThis trial studies people with HPV-positive oropharynx cancer whose tumors can be surgically removed. After surgery, patients are grouped by risk: low-risk patients get no further treatment, intermediate-risk get a lower dose of radiation, and high-risk get lower-dose radiation p…
Phase: PHASE2 • Sponsor: Heath Skinner • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Could chemo after surgery keep esophageal cancer at bay?
Disease control Recruiting nowThis trial investigates whether giving chemotherapy (docetaxel and nedaplatin) after surgery can prevent esophageal cancer from returning. Patients with a certain stage of thoracic esophageal squamous cell carcinoma who had their tumor fully removed are randomly assigned to recei…
Phase: NA • Sponsor: Sun Yat-Sen University Cancer Center • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
New drug aims to fight advanced stomach cancer when standard treatments fail
Disease control Recruiting nowThis phase 2 trial tests an experimental drug called SAR445877 in adults with advanced gastric or gastroesophageal junction cancer that has worsened after at least one prior treatment. The study includes about 30 participants and looks at whether the drug can shrink tumors. It is…
Phase: PHASE2 • Sponsor: Sanofi • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Triple-Drug cocktail aims to make inoperable liver cancer removable
Disease control Recruiting nowThis study tests whether combining an immunotherapy drug (camrelizumab), a targeted therapy (rivoceranib), and liver-directed chemotherapy (HAIC) can shrink intermediate-to-advanced liver tumors enough to allow surgical removal. About 400 adults with potentially resectable hepato…
Phase: PHASE2, PHASE3 • Sponsor: Shanghai Zhongshan Hospital • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Which fluid lifts better? trial tests two solutions for removing esophageal cancer without surgery
Disease control Recruiting nowThis trial compares two liquids—hyaluronic acid and hydroxyethylamide—used to lift early-stage esophageal tumors before endoscopic removal. Doctors inject one of these solutions under the cancer to create a cushion, making it safer and easier to cut out. The study measures how mu…
Phase: NA • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Protein-Wrapped chemo aims to hit tumors harder, spare healthy cells
Disease control Recruiting nowThis trial tests SPEDOX-6, a version of the chemotherapy drug doxorubicin wrapped in a protein shell, in people with advanced solid tumors such as soft-tissue sarcoma, triple-negative breast cancer, non-small cell lung cancer, cervical cancer, ovarian cancer, and certain pancreat…
Phase: PHASE1, PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Could a 'Sandwich' of drugs beat Full-Course immunotherapy for a tough head and neck cancer?
Disease control Recruiting nowThis phase III trial tests whether a shorter, 'immune sandwich' regimen works as well as full-course immunotherapy for locally advanced nasopharyngeal carcinoma. The experimental group gets induction chemotherapy plus two immune-targeting drugs (toripalimab and nimotuzumab), then…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Food aid may boost cancer treatment completion in food-insecure patients
Disease control Recruiting nowThis study looks at whether providing food assistance—like food boxes and produce vouchers—helps cancer patients who struggle with food insecurity stay on track with their treatment. Researchers will compare patients who receive six months of food support to those who get standar…
Phase: NA • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental shot aims to rev up immune system against advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called ACM-CpG, given as a shot into the muscle, in people with advanced solid tumors that have not responded to standard immunotherapy. The drug is designed to activate the immune system to attack tumors. The study aims to find the s…
Phase: PHASE1 • Sponsor: National Cancer Centre, Singapore • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental pill aims to shield the liver during cancer treatment
Disease control Recruiting nowThis trial tests whether an experimental drug called FB-1603 can protect liver function in people with liver cancer who are receiving a standard procedure called transarterial chemoembolization (TACE). Participants take either a low dose, a high dose, or a placebo capsule daily f…
Phase: PHASE1, PHASE2 • Sponsor: Febico Biomedical Corp. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Chemo, immunotherapy, and targeted radiation join forces against bile duct cancer
Disease control Recruiting nowThis study tests whether combining chemotherapy (gemcitabine and cisplatin) with an immunotherapy drug (durvalumab) and a targeted radiation treatment (Yttrium-90 microspheres) can shrink tumors in people with locally advanced bile duct cancer that cannot be removed by surgery. T…
Phase: PHASE2 • Sponsor: Inova Health Care Services • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug duo aims to keep advanced nasopharyngeal cancer in check
Disease control Recruiting nowThis Phase III trial tests whether adding an experimental drug called becotatug vedotin to standard anti-PD1 immunotherapy can better control advanced nasopharyngeal carcinoma that has spread or returned. About 86 adults whose cancer has stabilized after initial chemoimmunotherap…
Phase: PHASE3 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
Experimental drug PA5 targets arginine to starve advanced cancers
Disease control Recruiting nowThis phase 1 trial tests an experimental drug called PA5 in adults with advanced solid tumors that have not responded to standard treatments. PA5 is designed to break down arginine, an amino acid some cancers need to grow. The study aims to find the safest dose and check for side…
Phase: PHASE1 • Sponsor: Chongqing Peg-Bio Biopharm Co., Ltd. • Aim: Disease control
Last updated Jul 16, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThis study tests an experimental therapy called YH02, a genetically modified virus designed to infect and destroy cancer cells. It is given as an injection directly into tumors in people with advanced solid tumors (such as head and neck cancer, breast cancer, or melanoma) that ha…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Triple chemo cocktail aims to clear deadly bowel blockages in advanced stomach cancer
Disease control Recruiting nowThis phase II trial tests a modified combination of three chemotherapy drugs—docetaxel, oxaliplatin, and fluorouracil—in people with advanced stomach or gastroesophageal junction cancer that has spread to the lining of the abdomen (peritoneal carcinomatosis) and caused a bowel bl…
Phase: PHASE2 • Sponsor: Sixth Affiliated Hospital, Sun Yat-sen University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Timing of local therapy may boost immunotherapy in Hard-to-Treat esophageal cancer
Disease control Recruiting nowThis study investigates whether starting local treatments like radiation or surgery early or later alongside immunotherapy improves outcomes for people with esophageal cancer that has spread to a limited number of spots. Participants receive standard chemoimmunotherapy plus local…
Sponsor: Fudan University • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Common diabetes drug may slow rare abdominal cancer
Disease control Recruiting nowThis trial tests whether metformin, a common diabetes medication, can help people with pseudomyxoma peritonei, a rare cancer that spreads in the abdomen. The study includes adults whose cancer has returned or cannot be surgically removed. Researchers will measure how many partici…
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Immunotherapy-Chemo combo aims to outperform standard chemoradiation in esophageal cancer
Disease control Recruiting nowThis clinical trial compares two approaches for treating locally advanced esophageal squamous cell carcinoma before surgery. One group receives the immunotherapy drug cardonilizumab combined with chemotherapy, while the other receives standard chemoradiotherapy. The goal is to se…
Phase: PHASE2 • Sponsor: Tongji Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Chemo-loaded microspheres aim to starve liver tumors from within
Disease control Recruiting nowThis trial tests a treatment for people with liver cancer that cannot be removed by surgery. Tiny beads called BioPearl microspheres are loaded with the chemotherapy drug doxorubicin and injected into the blood vessels feeding the tumor. The beads block blood flow and release the…
Phase: NA • Sponsor: Terumo Europe N.V. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Blood test may decide who needs chemo after colon cancer surgery
Disease control Recruiting nowThis trial investigates whether a blood test that detects tiny bits of tumor DNA (circulating tumor DNA) can help decide which patients with stage II colon cancer need chemotherapy after surgery. Patients whose blood test is positive for tumor DNA receive chemotherapy (mFOLFOX6),…
Phase: PHASE3 • Sponsor: Centre Hospitalier Universitaire Dijon • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Tailored rehab program aims to help young adults reclaim life after cancer
Disease control Recruiting nowThis trial tests a 16-week rehabilitation program called YATAC, designed specifically for young adults aged 18–39 who have or have had cancer. The program includes physical activity, mental health support, nutrition advice, and help with education or work. Researchers want to see…
Phase: NA • Sponsor: University of Aarhus • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Immunotherapy may replace chemo in anal cancer treatment
Disease control Recruiting nowThis phase 3 trial tests whether the immunotherapy drug sintilimab can replace the chemotherapy drug mitomycin in standard chemoradiation for limited-stage anal squamous cell carcinoma. About 350 patients who have not yet been treated will receive either the standard regimen (rad…
Phase: PHASE3 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
New Antibody-Drug combo takes on Hard-to-Treat pancreatic cancer
Disease control Recruiting nowThis study tests a new drug called IBI343, given together with standard chemotherapy pills (capecitabine) and sometimes another chemo drug (oxaliplatin), in people whose advanced pancreatic cancer has stopped responding to initial treatment. The goal is to find a safe dose and se…
Phase: PHASE1, PHASE2 • Sponsor: Zhejiang Cancer Hospital • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Triple attack on stomach cancer: radiation, chemo, and a smart antibody
Disease control Recruiting nowThis trial tests a new approach for people with advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. It combines standard chemotherapy (CAPOX) and radiation with an experimental drug called SHR-1701, which targets two proteins (PD-L1 and TGF-β) …
Phase: PHASE2 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New blood test could spot 10 cancers before symptoms start
Diagnosis Recruiting nowThis study is testing whether a new blood test can screen for many types of cancer at once. Researchers will enroll 24,000 adults aged 45-75 who do not have cancer. Participants will be randomly assigned to one of two blood test groups or a control group. The goal is to see how w…
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
A simple blood draw could spot colorectal cancer early
Diagnosis Recruiting nowThis study is testing whether a blood test can accurately identify colorectal cancer or polyps in adults referred for suspected lower GI cancer. Participants provide a blood sample during their routine diagnostic visit, and their results are compared to their final diagnosis. The…
Sponsor: Queen Mary University of London • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new blood test spot colorectal cancer return earlier?
Diagnosis Recruiting nowThis trial compares two blood tests—Haystack and Signatera—that look for tiny traces of tumor DNA in the blood after surgery for stage II-IV colorectal cancer. The goal is to see which test is better at detecting minimal residual disease, which could signal that cancer may come b…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Blood test could outshine ultrasound in liver cancer screening
Diagnosis Recruiting nowThis phase IV trial will enroll 5,500 people with liver cirrhosis or chronic hepatitis B—conditions that raise liver cancer risk. Participants are randomly assigned to either standard ultrasound screening or a new blood test called GALAD, which measures three proteins. The goal i…
Phase: PHASE4 • Sponsor: University of Texas Southwestern Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer light up hidden cancers?
Diagnosis Recruiting nowThis trial is testing whether a new radioactive tracer, called 68Ga-SorB, can help doctors see certain solid tumors on PET/CT scans. The tracer targets sortilin, a protein that is often found on cancer cells. About 50 adults with melanoma, liver, lung, breast, pancreatic, or ovar…
Phase: NA • Sponsor: Peking University Third Hospital • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
A new imaging agent could tell doctors which liver cancers will resist immunotherapy
Diagnosis Recruiting nowThis trial is testing whether a special PET/CT scan using 18F-fluorocholine, along with a liquid biopsy, can predict how well patients with inoperable liver cancer (hepatocellular carcinoma) will respond to immunotherapy. The study enrolls adults with this type of liver cancer wh…
Phase: PHASE2 • Sponsor: Queen's Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new PET tracer reveal a key cancer target?
Diagnosis Recruiting nowThis trial is testing whether a new PET imaging agent can safely and effectively detect a protein called MMP14 on solid tumors. The study will involve about 30 adults with various solid tumors, such as melanoma, lung, or breast cancer. Each participant will receive the experiment…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
A new test could reveal how radiation affects the liver
Diagnosis Recruiting nowThis pilot study explores whether a combination of advanced MRI scans and a blood test called HepQuant DuO can measure liver function in people receiving radiation therapy for liver cancer. The study will enroll about 40 adults with liver cancer or liver metastases. The goal is t…
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Diagnosis
Last updated Aug 13, 2026 00:00 UTC
-
New imaging tool could make mouth biopsies more accurate
Diagnosis Recruiting nowThis study tests a new imaging device called the Active Biopsy Guidance System to help doctors decide when and where to take tissue samples (biopsies) from mouth lesions. About 90 adults with suspicious mouth spots or a history of oral cancer will participate. The goal is to see …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
New scan could spot pancreatic cancer more clearly
Diagnosis Recruiting nowThis study tests a special PET scan that uses a radioactive tracer called 68Ga-FAPI-46 to highlight pancreatic cancer cells. The goal is to see if this scan can find tumors more accurately than current methods. About 130 adults with early-stage pancreatic cancer will get the scan…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a radioactive tracer light up hidden tumors? a new trial aims to find out
Diagnosis Recruiting nowThis Phase I trial is testing an experimental imaging drug, 203Pb-RMX-VH-PIB, to see how it spreads through the body and how much radiation reaches different organs. The study includes adults with glioblastoma (a type of brain cancer) or pancreatic cancer. Participants receive a …
Phase: PHASE1 • Sponsor: Radiomedix, Inc. • Aim: Diagnosis
Last updated Aug 09, 2026 00:00 UTC
-
New imaging tracer could spot tumors more clearly
Diagnosis Recruiting nowThis early-stage study tests a new injection called [18F]LY4214835 to see if it is safe and how it spreads in the body. It includes healthy volunteers and people with cancer. The goal is to improve how doctors see tumors using imaging scans.
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
New blood test could spot cancer early – 6,000+ join study
Diagnosis Recruiting nowThis study tests a new blood and urine test that looks for DNA markers to detect cancer early and identify where it started. Researchers at Mayo Clinic will enroll about 6,150 people, including those with and without cancer. The goal is to see if these tests can accurately find c…
Sponsor: Mayo Clinic • Aim: Diagnosis
Last updated Aug 08, 2026 00:03 UTC
-
New laser camera could revolutionize oral cancer diagnosis
Diagnosis Recruiting nowThis study is testing a special camera that uses a laser to take microscopic pictures of suspicious spots inside the mouth. The goal is to see if these images can help doctors diagnose oral cancers and guide surgery. About 140 people with oral cancer will have their lesions image…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Diagnosis
Last updated Aug 06, 2026 00:00 UTC
-
One drop, many cancers? a rapid test aims to spot cancer signals in blood, urine, or saliva
Diagnosis Recruiting nowThis study evaluates a rapid test called Methylscape that measures DNA methylation patterns in body fluids like blood, urine, or saliva. The goal is to see if it can detect a cancer signal and even predict where the cancer started, using a single sample. Researchers will compare …
Sponsor: Centro de Tratamiento e Investigación sobre Cáncer, Luis Carlos Sarmiento Angulo • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Can a tracer that hunts unstable iron light up hidden tumors?
Diagnosis Recruiting nowThis phase 1 trial is testing whether a new imaging tracer called 18F-TRX can safely and effectively detect solid tumors using PET scans. The tracer targets unstable iron levels, which are often elevated in cancerous tissue. Adults with advanced solid tumors, including certain pr…
Phase: PHASE1 • Sponsor: Rahul Aggarwal • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
A sponge you swallow could detect esophageal cancer before it spreads
Diagnosis Recruiting nowThis trial tests a new way to spot esophageal cancer early using a swallowable sponge called EsophaCap, which collects cells from the esophagus. A lab test then looks for DNA changes linked to cancer. The study enrolls adults with or suspected of having esophageal cancer, as well…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Diagnosis
Last updated Jul 25, 2026 00:00 UTC
-
Can a simple swab predict who needs less radiation?
Diagnosis Recruiting nowThis trial is testing a new electrochemical method to monitor HPV infection in patients with head and neck cancers, specifically oropharyngeal carcinoma. The goal is to see if tracking HPV DNA levels during treatment can help personalize therapy, potentially allowing some patient…
Phase: NA • Sponsor: Masaryk Memorial Cancer Institute • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
New imaging agent could sharpen cancer detection
Diagnosis Recruiting nowThis trial evaluates a radioactive tracer called 68Ga-DOTA/NOTA-FAPI-04, given as a single injection before a PET/CT scan, to see if it can better identify primary tumors and metastases in people with various cancers. Researchers will measure how strongly the tracer accumulates i…
Phase: EARLY_PHASE1 • Sponsor: First Affiliated Hospital of Fujian Medical University • Aim: Diagnosis
Last updated Jul 23, 2026 00:00 UTC
-
Could a simple blood test replace invasive tissue biopsies for cancer genetics?
Diagnosis Recruiting nowThis study compares a blood test (liquid biopsy) to the standard tissue biopsy for finding genetic changes in advanced solid tumors. The goal is to see if the liquid biopsy can accurately detect the same genetic alterations as the tissue sample. If it works, patients might avoid …
Phase: NA • Sponsor: Centre Antoine Lacassagne • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New PET tracer aims to spot hidden cancer spread in the abdomen
Diagnosis Recruiting nowThis phase 2 study tests whether a radioactive tracer called [68Ga]BED003 can improve PET/CT scans for detecting cancer in the peritoneum (the lining of the abdomen). The trial includes adults with colorectal, ovarian, gastric, pancreatic, or a type of breast cancer. Researchers …
Phase: PHASE2 • Sponsor: Blue Earth Diagnostics • Aim: Diagnosis
Last updated Jul 17, 2026 00:00 UTC
-
Could a simple blood test catch pancreatic cancer before It's too late?
Diagnosis Recruiting nowThis study is testing a new blood test that looks at tiny particles called exosomes and their microRNA content, analyzed by machine learning, to detect pancreatic cancer early. It involves 600 people at high risk due to family history or pancreatic cysts. The goal is to see if th…
Sponsor: Università Vita-Salute San Raffaele • Aim: Diagnosis
Last updated Jul 16, 2026 00:00 UTC
-
Simple blood test aims to catch liver cancer before It's too late
Diagnosis Recruiting nowThis study is testing a new blood test designed to detect liver cancer (hepatocellular carcinoma) early in people who are at high risk because they have cirrhosis. The test looks for specific DNA markers and proteins in the blood that may signal the presence of cancer. Researcher…
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
Simple blood test aims to spot multiple cancers early
Diagnosis Recruiting nowThis study collects blood samples from healthy people, those with benign diseases, and cancer patients to develop a multi-analyte blood test. The test looks for DNA methylation markers that may indicate the presence of various cancers, especially liver cancer. Researchers aim to …
Sponsor: Helio Genomics • Aim: Diagnosis
Last updated Jul 12, 2026 00:00 UTC
-
New PET tracer targets cancer cells for sharper tumor imaging
Diagnosis Recruiting nowThis study tests a new imaging agent called F18 FBPA, which is designed to light up cancer cells during a PET/CT scan. The agent targets a protein often found on solid tumors, potentially making tumors easier to see. Researchers want to find the best dose and timing for the scan,…
Phase: PHASE1, PHASE2 • Sponsor: Heron Neutron Medical Corp. • Aim: Diagnosis
Last updated Jul 11, 2026 00:00 UTC
-
Can you wait 10 years? new study tests longer colonoscopy intervals for Low-Risk polyps
Prevention Recruiting nowThis study looks at whether people who have had 1 or 2 small, non-cancerous polyps removed can safely wait 10 years for their next colonoscopy instead of the usual 5 years. About 9,500 adults aged 45-69 will be randomly assigned to one of two schedules: a colonoscopy at 5 and 10 …
Phase: NA • Sponsor: NRG Oncology • Aim: Prevention
Last updated Aug 06, 2026 00:00 UTC
-
New study aims to ease cancer journey for LGBTQ+ patients and loved ones
Symptom relief Recruiting nowThis study is testing a program called FOCUS ON US, designed to help sexual and gender minority (LGBTQ+) cancer patients and their caregivers. The program includes five sessions covering topics like family involvement, coping skills, and symptom management. Researchers want to se…
Phase: NA • Sponsor: Charles Kamen • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Cancer injection satisfaction study recruits 700 patients
Symptom relief Recruiting nowThis study observes about 700 people with lung or liver cancer who are already receiving atezolizumab as a shot under the skin. Researchers want to see how satisfied patients are with this treatment and how it affects their quality of life. The study does not test a new drug but …
Sponsor: Hoffmann-La Roche • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
New drug aims to ease painful mouth sores for head and neck cancer patients
Symptom relief Recruiting nowThis phase II trial tests whether adding BMX-001 to standard symptom management can reduce severe mouth sores in head and neck cancer patients receiving chemoradiation. About 98 participants will receive either BMX-001 or a placebo alongside usual care. The goal is to see if BMX-…
Phase: PHASE2 • Sponsor: NRG Oncology • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
New camera trick could slash stomach surgery risks
Symptom relief Recruiting nowThis study tests whether using a special imaging technique called Red Dichromatic Imaging (RDI) throughout the entire ESD procedure can reduce serious complications like bleeding and perforation, and shorten surgery time. About 640 adults with early stomach cancer or precancerous…
Phase: NA • Sponsor: Xijing Hospital of Digestive Diseases • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Could a simple activity-based therapy lift depression in older cancer survivors?
Symptom relief Recruiting nowThis study tests whether a short psychotherapy called brief behavioral activation (BBA) can reduce depression and anxiety and improve well-being in older adults who have survived cancer. BBA encourages people to set goals and engage in enjoyable or rewarding activities to change …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
Acupuncture may restore periods lost to chemo in young cancer survivors
Symptom relief Recruiting nowThis study looks at whether acupuncture can help young women (ages 15-40) with cancer get their periods back after chemotherapy caused them to stop. About 60 participants will receive acupuncture or usual care. Researchers will measure how many people join and finish the study, a…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 18, 2026 04:00 UTC
-
A good Night's sleep: could a simple program ease Cancer's toll on rest?
Symptom relief Recruiting nowThis study explores whether a brief behavioral program can help cancer patients and their sleep partners get better rest. The program teaches techniques like limiting time in bed and going to bed only when sleepy, aiming to improve sleep efficiency. Participants, who are couples …
Phase: NA • Sponsor: University of Miami • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Acupuncture and ear seeds may help cancer patients need less pain medication
Symptom relief Recruiting nowThis study tests whether adding electroacupuncture and ear acupoint pressing beans to a standard opioid painkiller can better relieve severe cancer pain that doesn't respond to usual treatments. About 30 adults with refractory cancer pain will receive the combination for two week…
Phase: EARLY_PHASE1 • Sponsor: Qinghai Red Cross Hospital • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
Writing away the worry: new study tests expressive writing for cancer survivors
Symptom relief Recruiting nowThis study tests whether expressive writing—reading and writing about positive experiences—can help cancer survivors manage stress. About 414 survivors will participate from home using a computer or smartphone. The goal is to see if this simple activity can lower stress and impro…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 16, 2026 00:00 UTC
-
New support program hopes to ease Cancer's toll on chinese patients
Symptom relief Recruiting nowThis study tests a support program for Chinese cancer patients and survivors that includes education sessions, counseling, and peer support. The program is delivered by phone or video call. Researchers want to see if the program is practical and whether it improves quality of lif…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
New telehealth program aims to ease depression and fatigue in latino cancer patients
Symptom relief Recruiting nowThis study tests a special mental health program called DESCANSO/REST for Spanish-speaking Latino cancer patients who feel depressed, tired, or have trouble sleeping. The program is delivered through telehealth (video or phone calls). Researchers want to see if it is practical an…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Magic mushroom therapy could help cancer survivors beat depression
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, combined with talk therapy can safely help cancer survivors with depression or anxiety. Twenty adults who have finished cancer treatment and have no brain involvement will receive a single dose of psil…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
Early jaw exercises may prevent lockjaw in cancer patients
Symptom relief Recruiting nowThis study tests whether closely watching jaw movement and starting physical therapy early can prevent or reduce trismus (jaw tightness) in people receiving radiation for head and neck cancer. Thirty adults will be checked weekly during treatment and given jaw exercises if their …
Phase: NA • Sponsor: University of Alberta • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New program aims to ease burden on caregivers of cancer and diabetes patients
Symptom relief Recruiting nowThis study tests a program called enCompass Humana, which provides coaching and resources to unpaid caregivers of adults with both cancer and diabetes. The goal is to see if the program is practical and helpful for caregivers, improving their coping skills and reducing loneliness…
Phase: NA • Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Free food and online cooking classes could help cancer survivors thrive
Symptom relief Recruiting nowThis study looks at whether giving cancer survivors free healthy food and online cooking lessons can improve their health and well-being. The program is for survivors who struggle to afford food and are treated at a safety-net hospital. Researchers will check if the program is sa…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
New program aims to ease cancer Patients' pain and depression
Symptom relief Recruiting nowThis study tests a program called CARES that provides cancer patients with integrated screening and stepped care for symptoms like pain and depression. About 1,750 adults with cancer will be randomly assigned to CARES or standard care. The goal is to see if CARES improves quality…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
Dance your way to better sleep: latin moves tested in cancer survivors
Symptom relief Recruiting nowThis study looks at whether a culturally tailored Latin dance program can help Hispanic cancer survivors sleep better. Researchers will enroll 40 adults who have finished their main cancer treatment but still have trouble sleeping. Participants will either take dance classes or c…
Phase: NA • Sponsor: Rutgers, The State University of New Jersey • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
New pill aims to stop chemo sickness in its tracks
Symptom relief Recruiting nowThis study tests an experimental drug called LY3537021 to see if it can better control nausea and vomiting caused by chemotherapy in adults with cancer. About 204 participants will receive either the drug or a placebo, and researchers will track who has no vomiting and does not n…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New shot aims to ease depression and anxiety in cancer and chronic disease patients
Symptom relief Recruiting nowThis study tests whether a single injection of RE104 can reduce symptoms of depression or mixed depression and anxiety in people with adjustment disorder caused by a serious medical illness like cancer, ALS, multiple sclerosis, Parkinson's disease, or idiopathic pulmonary fibrosi…
Phase: PHASE2 • Sponsor: Reunion Neuroscience Inc • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
New program aims to cut hospital visits by helping cancer patients speak up
Symptom relief Recruiting nowThis trial tests an educational program called A-PACT for people with solid tumors who are at high risk of decline. Trained lay health workers coach patients on how to discuss their care goals and end-of-life wishes with their medical team. The study will see if this reduces unpl…
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
New algorithm aims to keep chemo on track for stomach and colon cancers
Symptom relief Recruiting nowThis study tests whether a special algorithm called PAGODA can reduce unplanned delays during FOLFOX chemotherapy for gastrointestinal cancers like colon, stomach, and esophageal cancer. About 420 participants will be randomly assigned to either standard care or the algorithm-gui…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
A hug in a blanket: could deep pressure calm cancer infusion anxiety?
Symptom relief Recruiting nowThis trial tests whether using a weighted blanket during a first cancer infusion (like chemotherapy) can lower anxiety and distress compared to a regular blanket. The idea is that the deep touch pressure from the blanket may calm the nervous system and increase feelings of well-b…
Phase: NA • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Home workouts via video calls could ease cancer side effects
Symptom relief Recruiting nowThis study tests whether cancer patients can complete a supervised exercise program from home using video calls. The program includes resistance training with dumbbells and aerobic exercise. Researchers want to see if this approach is practical and helps patients maintain functio…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Magic mushroom compound tested for cancer pain that opioids Can't touch
Symptom relief Recruiting nowThis study tests whether psilocybin, the active ingredient in magic mushrooms, can help relieve severe pain in people with advanced cancer when opioids don't work. Fifteen participants will receive psilocybin capsules along with therapy sessions. The goal is to see if this approa…
Phase: PHASE2 • Sponsor: Yvan Beaussant, MD, MSci • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Common nausea pill may tame immunotherapy's harsh side effects in liver cancer
Symptom relief Recruiting nowThis study tests whether ondansetron, a drug typically used for nausea, can lower the risk and severity of side effects from immunotherapy in people with liver cancer. About 134 patients will receive ondansetron alongside their standard cancer treatment. The goal is to see if thi…
Phase: PHASE2 • Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
New trial aims to ease cancer Patients' breathlessness with tailored oxygen and relaxation techniques
Symptom relief Recruiting nowThis study tests a personalized program called SPOT-ON for cancer patients suffering from severe shortness of breath. Participants will receive a combination of breathing techniques, relaxation methods, posture adjustments, and oxygen-based therapies, either starting early or aft…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
New pill aims to tame flushing and diarrhea in rare cancer syndrome
Symptom relief Recruiting nowThis Phase 3 trial tests whether the experimental drug paltusotine can reduce flushing and diarrhea in adults with carcinoid syndrome caused by neuroendocrine tumors. About 141 participants will receive either paltusotine or a placebo daily for 12 weeks. The study measures how mu…
Phase: PHASE3 • Sponsor: Crinetics Pharmaceuticals Inc. • Aim: Symptom relief
Last updated Aug 06, 2026 00:00 UTC
-
Can a smartphone app teach resilience to young cancer patients?
Symptom relief Recruiting nowThis pilot trial tests whether a mobile app version of a resilience-building program, called mPRISM, is acceptable and helpful for adolescents and young adults recently diagnosed with cancer. The app teaches coping skills like stress management, goal-setting, and reframing negati…
Phase: NA • Sponsor: Seattle Children's Hospital • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Mushroom extract put to the test for advanced cancer Well-Being
Symptom relief Recruiting nowThis trial tests whether Yunzhi essence, a mushroom extract from Coriolus versicolor, can improve quality of life for people with advanced cancer. Participants take either the extract or a placebo for six months, while researchers measure changes in well-being, survival, and immu…
Phase: PHASE2 • Sponsor: Chinese University of Hong Kong • Aim: Symptom relief
Last updated Aug 01, 2026 00:00 UTC
-
Could palliative care ease the burden of childhood cancer trials?
Symptom relief Recruiting nowThis study looks at whether adding pediatric palliative care consultations can improve quality of life for children with cancer and their families while they take part in early-phase (phase 1) clinical trials. Phase 1 trials test new drugs for safety, but they can cause side effe…
Phase: EARLY_PHASE1 • Sponsor: Phoenix Children's Hospital • Aim: Symptom relief
Last updated Jul 31, 2026 00:00 UTC
-
Pulsing radiation may spare esophageal cancer patients from agonizing throat pain
Symptom relief Recruiting nowThis trial tests whether giving radiation in tiny pulses (pulsed low-dose-rate) instead of the standard continuous dose can lower the risk of severe esophagitis—painful inflammation of the swallowing tube—during chemoradiation for esophageal cancer. About 50 people with stage II …
Phase: PHASE2 • Sponsor: Medical College of Wisconsin • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
Digital brain training may ease 'chemo brain' — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether two types of home-based digital cognitive training can help cancer survivors who have memory, attention, or thinking problems after chemotherapy. Participants will use either a computer program (BrainHQ) or a virtual reality cognitive training for 10 week…
Phase: NA • Sponsor: Biogipuzkoa Health Research Institute • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A single sheet of paper may transform how doctors deliver cancer news
Symptom relief Recruiting nowThis trial tests whether a one-page communication aid can improve how physicians and patients with cancer discuss the diagnosis. The aid, completed before the consultation, summarizes the patient's disclosure preferences and questions. Researchers will compare outcomes like patie…
Phase: NA • Sponsor: Chang Gung University • Aim: Symptom relief
Last updated Jul 30, 2026 00:00 UTC
-
A two-hour virtual session may help caregivers of children with cancer — a trial puts it to the test
Symptom relief Recruiting nowThis trial tests whether a short virtual program called GOLD can reduce anxiety and boost resilience in caregivers of children recently diagnosed with cancer. About 40 caregivers will either receive the two-hour GOLD session or standard information. The study measures how many ca…
Phase: NA • Sponsor: Stanford University • Aim: Symptom relief
Last updated Jul 29, 2026 00:00 UTC
-
Digital navigator aims to cut financial toxicity for young adults with cancer
Symptom relief Recruiting nowThis pilot study tests a hybrid intervention that combines a digital platform (Findhelp.org) with human navigation sessions to help adolescent and young adult cancer survivors manage financial and health-related social needs. Researchers will refine the approach with input from s…
Phase: NA • Sponsor: Columbia University • Aim: Symptom relief
Last updated Jul 25, 2026 00:00 UTC
-
Exercise before and after pancreatic cancer surgery may speed recovery and chemotherapy start
Symptom relief Recruiting nowThis study tests whether a personalized exercise program given before, during, and after Whipple surgery (a major operation for pancreatic cancer) helps patients recover faster and start chemotherapy sooner. Adults scheduled for Whipple surgery will receive an exercise plan tailo…
Phase: NA • Sponsor: University of Surrey • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Could a homeopathic remedy ease cancer treatment fatigue?
Symptom relief Recruiting nowThis study tests whether a homeopathic product called Encer can reduce fatigue in people with solid tumors who are starting chemotherapy or radiation therapy. Participants are randomly assigned to receive either Encer or a placebo, and their fatigue levels are tracked using a que…
Phase: EARLY_PHASE1 • Sponsor: Beaura for Para Pharmaceutical Products Trading LLC • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Could a geriatric checkup boost quality of life for older cancer survivors?
Symptom relief Recruiting nowThis study tests whether adding a geriatric assessment visit to the standard survivorship care plan improves quality of life and satisfaction for adults aged 65 and older who have completed chemotherapy with curative intent. Participants receive either the standard care plan alon…
Phase: NA • Sponsor: University of California, San Francisco • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could an ALS drug clear the fog of chemo brain?
Symptom relief Recruiting nowThis study tests whether riluzole, a drug already used for ALS, can help cancer survivors who struggle with memory, focus, and mental clarity after treatment — a condition called cancer-related cognitive impairment. Researchers will measure changes in a brain protein called BDNF …
Phase: PHASE2 • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jul 16, 2026 00:00 UTC
-
Could a Steroid-Sparing cocktail tame chemo nausea?
Symptom relief Recruiting nowThis phase 2 trial tests whether a combination of olanzapine and ondansetron can prevent nausea and vomiting caused by high-dose cisplatin chemotherapy in people with solid tumors. The approach aims to reduce steroid use by omitting dexamethasone on days 2 through 4. The study en…
Phase: PHASE2 • Sponsor: Mahidol University • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Simple habit hacks may help cancer survivors break free from too much sitting
Symptom relief Recruiting nowThis study tests whether an 8-week habit-based program can help cancer survivors reduce the time they spend sitting or lying down during the day. Participants receive weekly tips, check-in sessions, and a Fitbit to encourage more movement. The goal is to see if the program is pra…
Phase: NA • Sponsor: University of Toronto • Aim: Symptom relief
Last updated Jul 12, 2026 00:00 UTC
-
Personalized nutrition and exercise program aims to boost strength in frail cancer patients
Symptom relief Recruiting nowThis trial tests whether an 8-week program combining personalized nutrition advice and supervised home-based exercise is feasible for frail patients with advanced digestive cancers. Participants receive weekly visits from an exercise professional and dietitian, along with unsuper…
Phase: NA • Sponsor: Institut Curie • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Spinal pain pump may offer relief for cancer patients when opioids fail
Symptom relief Recruiting nowThis trial tests whether a small pump implanted in the abdomen that delivers pain medicine directly to the spinal fluid can improve quality of life for people with severe cancer pain that is not controlled by oral opioids. Participants are randomly assigned to get the pump or to …
Phase: NA • Sponsor: Universitair Ziekenhuis Brussel • Aim: Symptom relief
Last updated Jul 11, 2026 00:00 UTC
-
Scientists track Cancer's inner workings during radiation treatment
Knowledge-focused Recruiting nowThis study is for people with cervical or pancreatic cancer who are scheduled to receive chemoradiotherapy. Researchers will collect tumor samples, blood, and imaging data before, during, and after treatment to see how the tumor environment changes over time. The goal is to learn…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Cancer tissue bank opens to fuel research
Knowledge-focused Recruiting nowThis study collects tissue and fluid samples from up to 5,000 cancer patients to help researchers learn more about cancer and develop new tests and treatments. Samples are taken from routine procedures or from extra biopsies done just for research. The goal is to build a resource…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Patient stories could unlock new treatments for rare appendix cancer
Knowledge-focused Recruiting nowThis study is building a global patient registry to collect real-world information from people diagnosed with appendix cancer or pseudomyxoma peritonei (PMP), a rare condition where tumors spread in the abdomen. Participants and caregivers share details about their symptoms, trea…
Sponsor: Appendix Cancer Pseudomyxoma Peritonei Research Foundation • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Cancer data pooling study aims to connect the dots across trials
Knowledge-focused Recruiting nowThis study enrolls adults with cancer or benign tumors who are already participating in other trials at the National Cancer Institute. Researchers will collect and link medical records and research samples from all of a patient's past, current, and future studies. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
What happens when your genes reveal a surprise? new study seeks answers.
Knowledge-focused Recruiting nowThis study looks at people who have a gene variant (called a secondary finding) that was found during genetic testing for another reason. Researchers want to understand how these variants affect health, how people respond to the news, and whether they follow medical advice. Up to…
Sponsor: National Human Genome Research Institute (NHGRI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Cancer samples sought to unlock treatment secrets
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tumor samples from 500 adults with cancer or pre-cancerous conditions. Researchers will use these samples to learn more about how cancers behave and why some respond differently to treatments. Participants provide samples over time and …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
Which pathology method spots more cancer spread?
Knowledge-focused Recruiting nowThis trial compares two methods of examining colon cancer tissue after surgery: the European method, which relies solely on pathologists, and the Japanese method, which involves surgeons in finding lymph nodes. The goal is to see if the Japanese method is as accurate as the Europ…
Phase: PHASE3 • Sponsor: Russian Society of Colorectal Surgeons • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
AI may foresee lung complications after liver surgery
Knowledge-focused Recruiting nowThis study aims to build a digital early-warning system that uses machine learning to predict acute lung injury (ALI) in patients undergoing major liver surgery. By analyzing cardiopulmonary interaction characteristics, the model could help doctors identify at-risk patients early…
Sponsor: Beijing Tsinghua Chang Gung Hospital • Aim: Knowledge-focused
Last updated Aug 18, 2026 04:00 UTC
-
New blood test could spot pancreatic cancer sooner
Knowledge-focused Recruiting nowThis study aims to create a simple, minimally invasive test to find pancreatic cancer at an early stage and track how well treatment is working. Researchers will study 700 people with pancreatic cancer, pancreatitis, or pancreatic cysts. The goal is to identify biological markers…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can we predict dangerous side effects when combining radiation and immunotherapy?
Knowledge-focused Recruiting nowThis study is a large registry that tracks cancer patients who receive both radiotherapy and molecular therapies, such as immunotherapy. The goal is to better understand how these two treatments interact and to identify how often severe side effects occur. By collecting data from…
Sponsor: Centre hospitalier de l'Université de Montréal (CHUM) • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Massive global study tracks Durvalumab's Real-World impact on liver cancers
Knowledge-focused Recruiting nowThis study will follow about 4,490 adults with liver or bile duct cancer who are receiving durvalumab-based treatment as part of their routine care. Researchers want to see how long patients live and how well the treatment works outside of clinical trials. The goal is to gather r…
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
No treatment, just samples: new study aims to understand cancer immunity
Knowledge-focused Recruiting nowThis study collects blood and other biospecimens from adults with cancer to analyze immune-suppressing cells and genetic changes. Up to 1,750 participants will provide samples before and after chemotherapy. The goal is to better understand how cancer affects the immune system, bu…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New decision aid aims to empower advanced cancer patients in tough treatment talks
Knowledge-focused Recruiting nowThis study is creating a decision aid called TA-DA to help people with advanced cancer talk with their doctors about whether to try more treatments after several have already failed. The tool is designed to support shared decision-making. Researchers will test it with 155 patient…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
New cancer Drug's interaction with other meds under scrutiny in early trial
Knowledge-focused Recruiting nowThis early-phase study is looking at how a new drug called rezatapopt affects the way the body processes four common medications (metformin, rosuvastatin, repaglinide, and midazolam) in people with advanced solid tumors that have a specific genetic mutation (TP53 Y220C). The goal…
Phase: PHASE1 • Sponsor: PMV Pharmaceuticals, Inc • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Tumor DNA mapping may unlock personalized cancer therapies
Knowledge-focused Recruiting nowThis study explores whether analyzing the genetic makeup of a tumor biopsy can help identify advanced cancer patients who might benefit from targeted treatments. Adults with solid tumors who have no standard treatment options will have a biopsy of their lesion for molecular profi…
Phase: NA • Sponsor: Ulrik Lassen • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
What do young cancer patients really need? this survey aims to find out
Knowledge-focused Recruiting nowThis study asks 300 adolescents and young adults (ages 15-39) who have or had cancer to fill out questionnaires. The goal is to find gaps in education about exercise, sexual health, fertility, finances, and more. No treatment is given—just a survey to help improve future care.
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Virtual coach aims to boost diversity in cancer trials
Knowledge-focused Recruiting nowThis study tests whether a virtual community health educator (vCHE) can increase referrals to cancer clinical trials among diverse populations. Researchers will enroll 2,000 cancer patients and their caregivers across Florida. Participants interact with a computer-based agent tha…
Phase: NA • Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
New study checks if cancer drug olutasidenib changes how other medicines work
Knowledge-focused Recruiting nowThis study looks at how the cancer drug olutasidenib affects the way the body processes other medications. Researchers will give 16 adults with IDH1-mutated cancers a mix of test drugs before and during olutasidenib treatment to measure changes in drug levels. The goal is to ensu…
Phase: PHASE4 • Sponsor: Rigel Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Massive study aims to unlock genetic secrets of pediatric liver tumors
Knowledge-focused Recruiting nowThis study is collecting genetic and molecular data from up to 1,600 children with liver cancer and their families. Researchers will analyze DNA, gene activity, and immune cells to better understand what drives these rare tumors. The goal is to improve how these cancers are class…
Sponsor: University of Pittsburgh • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
AI platform aims to unlock Real-World cancer data on a massive scale
Knowledge-focused Recruiting nowThis study enrolls people diagnosed with cancer to build a large registry using Olivia, an AI-powered health platform. The platform will collect and combine electronic health records and patient-reported outcomes from over 1,000 healthcare systems. The goal is to create a compreh…
Sponsor: Tempus AI • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Cancer drug side effects under the microscope: what do they mean?
Knowledge-focused Recruiting nowThis study tracks 170 advanced cancer patients receiving anti-VEGF therapies to record side effects and see how the disease responds. Researchers hope to find patterns linking complications to treatment success. The goal is to help doctors better understand and manage these thera…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to bridge psychosocial care gap for cancer survivors
Knowledge-focused Recruiting nowThis study tests whether a routine digital screening followed by a supportive phone call can help cancer survivors get the emotional and social support they need after finishing primary treatment. Fifty adults who have completed cancer therapy will take part. The goal is to see i…
Phase: NA • Sponsor: University Hospital, Basel, Switzerland • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Can a swallowed balloon unlock the genetic secrets of esophageal cancer?
Knowledge-focused Recruiting nowThis research study is investigating how genetics and environmental factors contribute to the development of Barrett's esophagus and esophageal adenocarcinoma, a type of cancer. Researchers will collect samples from the esophagus using a non-endoscopic balloon capsule device, whi…
Sponsor: Case Western Reserve University • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Radiation aftermath: 700 cancer patients tracked for decades
Knowledge-focused Recruiting nowThis study follows about 700 cancer patients who have already received radiation therapy to understand the long-term side effects and how their disease progresses over time. No new treatments are given—researchers simply collect data from routine follow-up visits. The goal is to …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
Scientists seek tissue samples to unlock HIV and cancer mysteries
Knowledge-focused Recruiting nowThis study collects blood, bone marrow, and tissue samples from people with HIV, KSHV, or certain cancers to help researchers learn more about these diseases. Participants must be 18 or older and may have HIV, KSHV, or related conditions. No treatment is given; the goal is to gat…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New tool aims to bridge the gap in cancer conversations
Knowledge-focused Recruiting nowThis study tests a communication tool called TrialTalk™ in cancer clinics. The goal is to see if it helps doctors and patients talk more clearly about treatment options. About 30 patients and their doctors will fill out questionnaires before and after a regular visit. The study f…
Phase: NA • Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Scientists gather tumor samples to unlock new cancer treatments
Knowledge-focused Recruiting nowThis study collects tissue samples from people with solid tumors who are already scheduled for surgery or biopsy at the NIH Clinical Center. Researchers will use the samples to study the biology of cancer and identify new targets for therapy. Up to 1,800 adults and children (age …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Researchers launch major tissue bank to unlock secrets of mesothelioma
Knowledge-focused Recruiting nowThis study aims to collect blood, urine, tumor samples, and health data from up to 1,000 people with malignant mesothelioma or other cancers that express a protein called mesothelin. Participants will be followed over time to track the course of their disease. The goal is to buil…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Rare cancer study: does surgery help patients live longer?
Knowledge-focused Recruiting nowThis study looks at people with a rare and aggressive type of esophageal cancer that hasn't spread. It compares those who had surgery (with or without other treatments) to those who had non-surgical treatments like chemotherapy and radiation. The goal is to see which approach hel…
Sponsor: yi shen • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Does your doctor's screen time hurt your trust? new study investigates.
Knowledge-focused Recruiting nowThis study looks at how cancer patients view their doctor's compassion, communication, and professionalism when the doctor uses an electronic health record (EHR) during the visit. About 88 adults with cancer will watch videos or fill out questionnaires. The goal is to understand …
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Heart risk after chemo: scientists hunt for clues in your blood
Knowledge-focused Recruiting nowThis study is trying to understand why some people who get chemotherapy for cancer later develop heart issues, while others don't. Researchers will collect blood samples from 1,000 adults who have had chemotherapy, including those who had heart problems and those who didn't. By s…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
2000 volunteers help create a gold standard for cancer blood tests
Knowledge-focused Recruiting nowThis study collects blood and tissue samples from 2000 people—some with cancer and some without—to create a blinded reference set. Researchers will use these samples to evaluate how well new blood tests can detect many types of cancer early. The goal is to improve the accuracy of…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
New biobank aims to unlock secrets of Immunotherapy's harsh side effects
Knowledge-focused Recruiting nowThis study collects blood, tissue, and medical information from 240 cancer patients who have had serious side effects from immunotherapy. The goal is to store these samples in a national biorepository for future research. By studying these samples, scientists hope to better predi…
Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
HPV throat cancer study tracks hidden infections in women and partners
Knowledge-focused Recruiting nowThis study is checking how often women who have HPV-positive throat cancer, or whose partner has it, also have HPV infections in their genital or anal areas. Researchers will compare these rates to similar women without cancer. The goal is to learn more about how HPV spreads and …
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Which treatment for early stomach cancer offers the best Long-Term survival?
Knowledge-focused Recruiting nowThis study looks back at the medical records of about 5,000 people in China treated for early gastric cancer. It compares different treatment approaches—such as endoscopic removal, laparoscopic surgery, open surgery, or a combination—to see how they affect long-term survival and …
Sponsor: Beijing Friendship Hospital • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Who should tell relatives about cancer risk? new study tests best approach
Knowledge-focused Recruiting nowThis study looks at whether having a healthcare provider directly contact close relatives of people with newly diagnosed colorectal cancer leads to more genetic testing than having the patient share the information themselves. About 4,186 patients and their relatives will take pa…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
AI translates medical scans into plain english for cancer patients
Knowledge-focused Recruiting nowThis study is testing a new AI tool that creates patient-friendly summaries of radiology reports for people with cancer. The goal is to see if these easy-to-read summaries help patients better understand their scan results and reduce the number of questions doctors receive. About…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Chatbot vs. standard care: which boosts genetic testing in young cancer patients?
Knowledge-focused Recruiting nowThis study tests whether a digital chatbot can help more adolescents and young adults (AYA) with cancer get genetic counseling and testing compared to standard remote services. About 535 participants aged 18-39 will use either a chatbot or standard telehealth. The goal is to see …
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can AI predict who will respond to liver cancer drugs?
Knowledge-focused Recruiting nowThis study will use artificial intelligence to analyze CT scans and medical data from 400 liver cancer patients to predict who will respond to a common drug combination (atezolizumab and bevacizumab). The goal is to create a non-invasive tool that helps doctors choose the best tr…
Sponsor: First Affiliated Hospital of Wenzhou Medical University • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
New survey aims to give young cancer patients a stronger voice
Knowledge-focused Recruiting nowThis study is testing a new questionnaire called PRO-AYA, designed to measure quality of life in adolescents and young adults (ages 15-39) with cancer. Researchers want to see if the survey is reliable and accurate, including a Spanish version. 120 participants will fill out the …
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can a smartwatch help track cancer symptoms? small study aims to find out
Knowledge-focused Recruiting nowThis study is testing whether people in early-phase cancer trials will consistently wear a smartwatch and complete weekly symptom surveys on a phone app. Thirty participants will use the devices for 4 weeks. The goal is to see if this approach is practical and acceptable, not to …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists launch massive tumor repository to unlock cancer secrets
Knowledge-focused Recruiting nowThis study collects extra blood, urine, and tumor samples from children and adults with certain cancers to build a large tissue repository. Researchers will analyze these samples to learn more about the genetic and molecular makeup of these tumors. The goal is to support future s…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Can exercise boost brain power in young cancer survivors?
Knowledge-focused Recruiting nowThis study explores the link between physical activity and thinking skills in people who survived cancer as adolescents or young adults. Researchers will use computer-based brain games to measure memory and attention. The goal is to understand how exercise might help brain health…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Scientists hunt for hidden cancer clues in families
Knowledge-focused Recruiting nowThis study aims to learn how genes and the environment contribute to rare tumors and cancer risk in individuals and families. Researchers will collect medical histories, genetic samples, and health data from up to 500 participants of all ages. No treatment is given; the goal is t…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
New study tracks sleep problems after cancer diagnosis
Knowledge-focused Recruiting nowThis study follows 260 adults newly diagnosed with cancer who have no prior sleep issues. Researchers will track how insomnia develops over the first year, using questionnaires to measure sleep quality and severity. The goal is to understand what factors—like treatment type or em…
Sponsor: Centre Hospitalier Emile Roux • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
One dose may not fit all: blood tests could tailor cancer drug dosing
Knowledge-focused Recruiting nowThis study looks at whether measuring the amount of certain targeted cancer drugs in the blood can help find the best dose for each patient. It involves adults with advanced digestive cancers like colorectal, liver, and stomach tumors who are already taking these medications. By …
Phase: NA • Sponsor: UNICANCER • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can modern Radiotherapy's late effects be predicted?
Knowledge-focused Recruiting nowThis study follows a large group of children and young adults who received radiation therapy for cancer, to see how their health and quality of life evolve over many years. By collecting medical data and blood samples in a European registry, researchers aim to identify late effec…
Sponsor: Institut National de la Santé Et de la Recherche Médicale, France • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Can blood tests reveal how liver and bile duct cancers respond to treatment?
Knowledge-focused Recruiting nowThis study follows 150 adults with liver or bile duct cancer who are receiving standard treatments like surgery, ablation, or chemotherapy. Researchers will collect repeated blood samples before, during, and after treatment to analyze tumor DNA, immune cells, and proteins. The go…
Sponsor: Region Skane • Aim: Knowledge-focused
Last updated Aug 05, 2026 00:00 UTC
-
Reading Cancer's genetic playbook: a quest to match patients to the right experimental therapy
Knowledge-focused Recruiting nowThis observational study aims to identify genetic mutations in adults with advanced solid cancers who are being considered for or are already in early-phase clinical trials. By analyzing tumor and blood samples over time, researchers hope to understand how these mutations influen…
Sponsor: Institute of Cancer Research, United Kingdom • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can AI outthink cancer experts? a landmark trial pits five AIs against tumor boards
Knowledge-focused Recruiting nowThis trial asks whether five advanced AI models can match the treatment recommendations of expert tumor boards for cancer patients. Using 100 standardized synthetic cases across breast, lung, urological, digestive, and gynecological cancers, each AI and two independent tumor boar…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Aug 02, 2026 00:00 UTC
-
Can chemo and radiation steal fertility? a massive study aims to find out
Knowledge-focused Recruiting nowThis observational study tracks 7,000 men and women with cancer to see how treatments like chemotherapy, radiation, and immunotherapy affect fertility. In women, researchers measure a hormone called AMH to gauge ovarian reserve; in men, they analyze sperm quality. The goal is to …
Sponsor: Michael von Wolff • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC
-
Artificial intelligence may help decide who gets a liver first
Knowledge-focused Recruiting nowThis study tests whether artificial intelligence can more accurately predict which patients on the liver transplant waiting list are at highest risk of dying or becoming too sick for surgery. Researchers will follow 630 adults with severe liver disease or liver cancer across five…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
AI may outsmart current system for liver transplant priority
Knowledge-focused Recruiting nowThis European study is collecting health data from 4,500 adults listed for liver transplantation across 50 centers. The goal is to design and test new AI-based models that predict which patients are most likely to die or become too sick for transplant while waiting. If accurate, …
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Metabolic MRI may reveal hidden cancer responses and spare patients from surgery
Knowledge-focused Recruiting nowThis trial tests whether a new type of MRI, called hyperpolarized carbon-13 MRI, can better predict how rectal cancer responds to chemoradiotherapy. By tracking how cancer cells use energy, along with blood and tissue analysis, researchers hope to identify complete tumor response…
Sponsor: Chang Gung Memorial Hospital • Aim: Knowledge-focused
Last updated Jul 30, 2026 00:00 UTC
-
Stomach bug clues: can infection patterns forecast early cancer behavior?
Knowledge-focused Recruiting nowThis study looks at whether the presence and distribution of H. pylori bacteria in the stomach, along with tissue features of early gastric cancer, can help predict how the cancer will behave and what the long-term outlook may be. Researchers will analyze data from about 1,500 pe…
Sponsor: Chinese PLA General Hospital • Aim: Knowledge-focused
Last updated Jul 26, 2026 00:00 UTC
-
Web tool aims to empower rare cancer patients in genomic choices
Knowledge-focused Recruiting nowThis study tests an expanded web-based decision aid for people with cholangiocarcinoma, colorectal cancer, or multiple myeloma. Participants use the tool to choose which genomic results—such as cancer biomarkers or inherited risks—they want to receive. The goal is to see if the t…
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 25, 2026 00:00 UTC
-
Can a single drink reveal how alcohol triggers oral cancer?
Knowledge-focused Recruiting nowThis study investigates how acetaldehyde, a byproduct of alcohol, affects cells in the mouth and whether it may increase oral cancer risk. Healthy volunteers and individuals with Fanconi anemia (a condition linked to higher cancer risk) will consume a single dose of alcohol and p…
Phase: NA • Sponsor: Masonic Cancer Center, University of Minnesota • Aim: Knowledge-focused
Last updated Jul 24, 2026 00:00 UTC
-
Could a two-vein embolization trick turn inoperable liver tumors into operable ones?
Knowledge-focused Recruiting nowThis international registry collects medical images and health data from people with liver cancer or liver metastases who received a procedure called combined portal and hepatic vein embolization (PVE/HVE). The procedure blocks two sets of veins in the liver to encourage the heal…
Sponsor: Maastricht University Medical Center • Aim: Knowledge-focused
Last updated Jul 23, 2026 00:00 UTC
-
Building a biobank to unlock radiation Therapy's secrets
Knowledge-focused Recruiting nowThis research study collects tissue samples and medical information from people with cancer who are receiving radiation therapy, as well as from healthy volunteers. The goal is to create a long-term resource that scientists can use to study how cancer responds to radiation and to…
Sponsor: University of Texas Southwestern Medical Center • Aim: Knowledge-focused
Last updated Jul 19, 2026 00:00 UTC
-
What happens to young cancer patients after treatment? major study investigates
Knowledge-focused Recruiting nowThis study follows thousands of young adults (aged 18–40) diagnosed with solid tumors to see how their treatment affects organ preservation, fertility, and long-term quality of life. Researchers will compare them with older patients to understand unique needs. The goal is to impr…
Sponsor: Fudan University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Liver cancer registry aims to uncover new biomarkers from thousands of patients
Knowledge-focused Recruiting nowThis study creates a registry of up to 4000 people with primary liver cancer (hepatocellular carcinoma or biliary tract cancer) treated at San Raffaele Hospital. Researchers will collect medical records and, for some participants, biological samples to search for new biomarkers t…
Sponsor: IRCCS San Raffaele • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Gut instinct: listening to bowel sounds may reveal hidden clues about surgical recovery
Knowledge-focused Recruiting nowThis study looks at whether monitoring bowel sounds before and after colorectal cancer surgery can help doctors assess how well the intestines are recovering. Researchers will track 172 patients and compare bowel sound patterns with outcomes like time to first gas, ability to eat…
Sponsor: Zhongnan Hospital • Aim: Knowledge-focused
Last updated Jul 17, 2026 00:00 UTC
-
Giving cancer patients a say in genetic results may boost knowledge and satisfaction
Knowledge-focused Recruiting nowThis study looks at how letting cancer patients choose which genetic results they receive affects their understanding, expectations, and satisfaction. Adults with certain cancers (cholangiocarcinoma, multiple myeloma, or early-onset colon or rectal cancer) can join. Participants …
Phase: NA • Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC
-
DNA clues may reveal which esophageal cancers will return soon after surgery
Knowledge-focused Recruiting nowThis study looks at whether changes in DNA methylation—a type of epigenetic marker—can help predict if esophageal cancer will come back soon after surgery. Researchers will analyze tumor tissue from 150 patients who had their cancer removed and track who experiences a recurrence …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Biopsy DNA clues could spare esophageal cancer patients from futile chemo
Knowledge-focused Recruiting nowThis study investigates whether DNA methylation patterns in tumor biopsy samples can predict how well esophageal cancer patients will respond to chemotherapy. Researchers aim to develop a model that identifies patients unlikely to benefit from standard chemo drugs like Fluorourac…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jul 15, 2026 00:00 UTC
-
Dye test may predict dangerous pancreatic leaks after surgery
Knowledge-focused Recruiting nowThis study tests whether a dye called indocyanine green can help predict pancreatic leaks after pancreas surgery. Participants will receive the dye during surgery, and doctors will measure how well the pancreas tissue is getting blood flow. The goal is to see if this dye can iden…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Jul 11, 2026 00:00 UTC
-
Can daily activity ease fatigue in cancer survivors? a new study investigates
Knowledge-focused Recruiting nowThis study looks at how daily physical activity is linked to fatigue in people who have finished or are finishing cancer treatment. Participants wear a small activity monitor and report their fatigue levels. The goal is to understand whether being more active might help reduce fa…
Sponsor: University of Colorado, Denver • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC